US.LLY · Lilly (Eli)

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.5,
      "details": {
        "atrPct": 3.035259800409901,
        "turnoverUsdM": 5420.35733012976,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.LLY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 1085.28,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.1,
      "take_profit_price": 1213.191,
      "target_multiplier": 1.6,
      "technical_strength": 1.42,
      "take_profit_percent": 5
    },
    "positionPoints": 1.5,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.070519600819802,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 56,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 50,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 6
  },
  "market": {
    "ma20": 1188.053,
    "ma50": 1144.7834,
    "close": 1155.42,
    "prevClose": 1210.02,
    "avgVolume20": 2455877,
    "volumeRatio": 1.91,
    "changePercent": -4.51
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 6,
    "details": {
      "ret_5d": -0.025677317075227357,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 6,
      "vcp_bonus": 0,
      "vol_ratio": 1.9900625070259423,
      "ret_points": 0,
      "vol_points": 6,
      "range_ratio": 1.0053447717523285,
      "volat_points": 0,
      "day_range_pct": 0.028085084970484064,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 56,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 5.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 36,
        "contribution": 5.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 67,
        "contribution": 6.7
      },
      {
        "raw": 18.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 63,
        "contribution": 18.9
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 50,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 6/20分",
      "市場環境分析總分: 5.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.7/10分",
      "技術信號分析總分: 18.9/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 6,
      "市場環境": 5.4,
      "情緒分析": 6,
      "技術信號": 18.9,
      "風險管理": 6.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 5420.35733012976,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.LLY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 20.66
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 702.2489964000001,
                "ma50": 715.3588015999999,
                "name": "QQQ",
                "close": 683.54999,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.5820062000001,
                "ma50": 744.7240025799999,
                "name": "SPY",
                "close": 741.69,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.035259800409901,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141066673,
                "url": "https://finnhub.io/api/news?id=5317e3acec728c82f4293a7a1885fc5365ee9f9346e60036554a88c115baa5ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has joined Illumina's Billion Cell Atlas alliance as a foundational participant. The alliance is building what is described as the world's largest genome-wide genetic perturbation dataset. The Billion Cell Atlas is sequencing hundreds of millions of cells to map disease mechanisms and find new drug targets. Eli Lilly enters this genomic data effort with a stock that has seen very strong multi year appreciation. NYSE:LLY is trading at $1,210.02, with the share price up...",
                "category": "company",
                "datetime": 1785420453,
                "headline": "Eli Lilly (LLY) Joins Illumina’s Billion Cell Atlas For AI Drug Discovery"
              },
              {
                "id": 141064530,
                "url": "https://finnhub.io/api/news?id=233fa555eedd7625f54a5a375e9d86e540fc0826aa6fc15d56294a428e47e9ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]",
                "category": "company",
                "datetime": 1785410352,
                "headline": "Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma"
              },
              {
                "id": 141058900,
                "url": "https://finnhub.io/api/news?id=3b946c325725339a4480a062c4ff72f58a36a2164ab2cbcaea9621d0dd3c962f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Without you picking it, a single pharmaceutical stock may have quietly become one of the largest positions inside your funds.",
                "category": "company",
                "datetime": 1785361416,
                "headline": "How Much Eli Lilly (LLY) Are You Really Betting On?"
              },
              {
                "id": 141054031,
                "url": "https://finnhub.io/api/news?id=f79e98f0818c7403de7fa168099f007da064e195d777670372f0cf8b6b2cdef0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785333626,
                "headline": "Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?"
              },
              {
                "id": 141048281,
                "url": "https://finnhub.io/api/news?id=9a0a95dd4dd82e3947e5b235fdaee5bee14eafe1fc4e1863b57c79cde93d8e29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.",
                "category": "company",
                "datetime": 1785275102,
                "headline": "Eli Lilly (LLY) Rises Higher Than Market: Key Facts"
              },
              {
                "id": 141045190,
                "url": "https://finnhub.io/api/news?id=735a43ba3d19c4d05c735bc52ebace2e3812b9e0acdf5d504798b0860483b6e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.",
                "category": "company",
                "datetime": 1785251880,
                "headline": "Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings"
              },
              {
                "id": 141041257,
                "url": "https://finnhub.io/api/news?id=7e860275f31851a3380c6be69d64af1696b43a394fa503864f00c0dead7577a6",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Discover how the Best Dividend Stocks screen finds high-quality dividend payers like Eli Lilly (LLY) with sustainable growth, strong profitability, and healthy financials despite a low yield.",
                "category": "company",
                "datetime": 1785233444,
                "headline": "Eli Lilly (NYSE:LLY): A Quality Dividend Stock with Sustainable Growth and Strong Fundamentals"
              },
              {
                "id": 141036036,
                "url": "https://finnhub.io/api/news?id=af65196ac17f8ab0c7e78f696d4d665e249450d531ea5f10253facd4a98e3a95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Analysts have been lifting Eli Lilly price targets, with recent valuation work for the stock pointing to fair value of US$1,270.37 compared with the prior US$1,243.43 anchor. The shift lines up with a more constructive Wall Street stance as firms reassess the obesity and diabetes portfolio, retatrutide data, and Q2 earnings setup, with bullish targets clustering between roughly US$1,232 and US$1,600. Ahead, you will see how this evolving narrative, both bullish and cautious, can shape how you...",
                "category": "company",
                "datetime": 1785179297,
                "headline": "Eli Lilly (LLY) Stock Gets Fair Value Bump As Analysts Lift Targets On GLP1 Outlook"
              }
            ],
            "raw_source": [
              {
                "id": 141071363,
                "url": "https://finnhub.io/api/news?id=602f7b19387848f7523afd469bccaf5d43cc4d073c271b896f3262ce7b98a6c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock market jumped Thursday as Microsoft powered a big AI rebound. Apple and Amazon led earnings late.",
                "category": "company",
                "datetime": 1785447840,
                "headline": "Dow Jones Futures: Apple, Amazon Diverge Late; What To Do After AI Stocks Surge"
              },
              {
                "id": 141069743,
                "url": "https://finnhub.io/api/news?id=8ec42eaef439eaae7648bdbc5c90e852c9ed0d08fbb47fd2ec676334c0c2e797",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and",
                "category": "company",
                "datetime": 1785440768,
                "headline": "Sector Update: Healthcare Stocks Decline Late Afternoon"
              },
              {
                "id": 141068261,
                "url": "https://finnhub.io/api/news?id=6cfd92210b5cfa13302bbc1e31502135dc18dc38c6718516367d30a43337beee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the S",
                "category": "company",
                "datetime": 1785432931,
                "headline": "Sector Update: Healthcare Stocks Decline Thursday Afternoon"
              },
              {
                "id": 141069744,
                "url": "https://finnhub.io/api/news?id=d686d3419bdafcaeafad3d97863ed30744904dc6a46393475f4223f32585f7b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?",
                "category": "company",
                "datetime": 1785431700,
                "headline": "Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?"
              },
              {
                "id": 141068262,
                "url": "https://finnhub.io/api/news?id=8eff400141dbce2924a477056ce5fffc1ae38f568c25b2dd33f0b9de4f530cbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Expansion adds at least 400 jobs, taking Resilience's Ohio headcount above 1,400",
                "category": "company",
                "datetime": 1785428397,
                "headline": "Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal"
              },
              {
                "id": 141066673,
                "url": "https://finnhub.io/api/news?id=5317e3acec728c82f4293a7a1885fc5365ee9f9346e60036554a88c115baa5ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has joined Illumina's Billion Cell Atlas alliance as a foundational participant. The alliance is building what is described as the world's largest genome-wide genetic perturbation dataset. The Billion Cell Atlas is sequencing hundreds of millions of cells to map disease mechanisms and find new drug targets. Eli Lilly enters this genomic data effort with a stock that has seen very strong multi year appreciation. NYSE:LLY is trading at $1,210.02, with the share price up...",
                "category": "company",
                "datetime": 1785420453,
                "headline": "Eli Lilly (LLY) Joins Illumina’s Billion Cell Atlas For AI Drug Discovery"
              },
              {
                "id": 141067646,
                "url": "https://finnhub.io/api/news?id=41281070fe64681d4156832f8e5c670114b284aacd45b50acd6373e4ad03c545",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233502325/image_2233502325.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "MeiraGTx gene therapy upside: AAV2-hAQP1 for radiation xerostomia targets $3.7B market; Phase 2 data 2Q27. Click for more on MGTX stock.",
                "category": "company",
                "datetime": 1785416251,
                "headline": "Some Potential Merit Within MeiraGTx Holdings"
              },
              {
                "id": 141065421,
                "url": "https://finnhub.io/api/news?id=5fd8207c106f5b85a4831d162f1660904ceff3468e2a6862f90fe9c40b4d860c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CINCINNATI, July 30, 2026--Resilience today announced it has expanded its strategic partnership with Eli Lilly and Company to increase U.S. production of critical medicines.",
                "category": "company",
                "datetime": 1785412800,
                "headline": "Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply"
              },
              {
                "id": 141064530,
                "url": "https://finnhub.io/api/news?id=233fa555eedd7625f54a5a375e9d86e540fc0826aa6fc15d56294a428e47e9ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]",
                "category": "company",
                "datetime": 1785410352,
                "headline": "Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma"
              },
              {
                "id": 141068911,
                "url": "https://finnhub.io/api/news?id=cd558498e9a39157e1ae0870aca7fd9e3d6ee898e5784746df332c489fa4cd96",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://resilience.com/news/resilience-and-lilly-invest-750-million",
                "category": "company",
                "datetime": 1785407300,
                "headline": "Eli Lilly, Resilience Investing $750M To Expand Critical Medicines Manufacturing ​Capacity In U.S."
              },
              {
                "id": 141065422,
                "url": "https://finnhub.io/api/news?id=a93b9f6ddd0db8b30b247f0227240e7561ce98a1e09a7b5fcc64b26ea151443d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.",
                "category": "company",
                "datetime": 1785402720,
                "headline": "How Telix landed a $2.1 billion radiopharma deal with Regeneron"
              },
              {
                "id": 141066952,
                "url": "https://finnhub.io/api/news?id=2eddc54b3b0b3ec52bffeca1ee8733fd1ce0191ba45e660d066bb0f6bce4d5b9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/30/Chinas-Exports-Surge-Despite-US-Shortfal.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "CNBC's Mad Money Lightning Round: Cramer says Astera Labs (ALAB) is a buy, but doesn't care for Rigetti Computing (RGTI). Eli Lilly (LLY) is a classic own, don't trade. MakeMyTrip (MMYT) coverage initiated with Buy rating.",
                "category": "company",
                "datetime": 1785399322,
                "headline": "Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock"
              },
              {
                "id": 141058900,
                "url": "https://finnhub.io/api/news?id=3b946c325725339a4480a062c4ff72f58a36a2164ab2cbcaea9621d0dd3c962f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Without you picking it, a single pharmaceutical stock may have quietly become one of the largest positions inside your funds.",
                "category": "company",
                "datetime": 1785361416,
                "headline": "How Much Eli Lilly (LLY) Are You Really Betting On?"
              },
              {
                "id": 141058324,
                "url": "https://finnhub.io/api/news?id=15c4df4c5fb54cf1ba96872499789cc422bc41568843a346462416b65eec3566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "But is that performance sustainable?",
                "category": "company",
                "datetime": 1785360000,
                "headline": "Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now"
              },
              {
                "id": 141055664,
                "url": "https://finnhub.io/api/news?id=e61966a95d8d8343e6a238789e6279e8d9a2001564cea1c9641930aa99d4d8ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The telehealth provider shared patient health information with Snap and Meta, a federal complaint says.",
                "category": "company",
                "datetime": 1785353280,
                "headline": "Hims & Hers Stock Plunges After FTC Sues Over Alleged Privacy Violations"
              },
              {
                "id": 141067834,
                "url": "https://finnhub.io/api/news?id=96268c0fd67abf67b982d6afb9918b1b49f2a34ad206934829d280c30ab23d73",
                "image": "https://image.cnbcfm.com/api/v1/image/103507383-Lightning-Round.jpg?v=1698361043&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "\"Mad Money\" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.",
                "category": "company",
                "datetime": 1785351302,
                "headline": "Cramer's lightning round: Buy Astera Labs"
              },
              {
                "id": 141057017,
                "url": "https://finnhub.io/api/news?id=e2cfd77352aedb0d87503712841214980f53bb4ab61b29927df9b64aee78b575",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.",
                "category": "company",
                "datetime": 1785348670,
                "headline": "The Real Price of AbbVie Stock Is Cheaper Than You Think"
              },
              {
                "id": 141055687,
                "url": "https://finnhub.io/api/news?id=78fb6d7a827b11e1b3d187fe828c4cc86432c614601a42bdaccd5b91e80feef6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.",
                "category": "company",
                "datetime": 1785339540,
                "headline": "How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?"
              },
              {
                "id": 141054031,
                "url": "https://finnhub.io/api/news?id=f79e98f0818c7403de7fa168099f007da064e195d777670372f0cf8b6b2cdef0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785333626,
                "headline": "Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?"
              },
              {
                "id": 141052979,
                "url": "https://finnhub.io/api/news?id=70f5a2da103decf7e334246c05d58143ca2238deab2af29fe45d8419b3df0aff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly's pipeline is on track to pick up a handful of interesting new programs.",
                "category": "company",
                "datetime": 1785327960,
                "headline": "Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock"
              },
              {
                "id": 141052980,
                "url": "https://finnhub.io/api/news?id=5228ae4d4225c173b04a8e7d24353c1eeb99f5d47b558e1568b0c067521ab80e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Will this pharma company become a new leader in the weight loss market?",
                "category": "company",
                "datetime": 1785325800,
                "headline": "Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients"
              },
              {
                "id": 141052126,
                "url": "https://finnhub.io/api/news?id=529dee54f3bc7ee3eb94aa5566f19dc9c0ed643868526e09521e10fde417664a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.",
                "category": "company",
                "datetime": 1785325441,
                "headline": "Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth"
              },
              {
                "id": 141053885,
                "url": "https://finnhub.io/api/news?id=1f15877a1001ae15dd5a3cd545b026512debdef79ac455207e35e507121673e3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238013673/image_2238013673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Biogen Inc. upgraded to Buy: Q2 revenue +3%, LEQEMBI traction, and felzartamab catalysts drive upside. Click for this BIIB earnings update.",
                "category": "company",
                "datetime": 1785324567,
                "headline": "Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)"
              },
              {
                "id": 141051546,
                "url": "https://finnhub.io/api/news?id=0584590b496f606167d55dc0f933bfe7ffa13546b20d0b14b6d90c70a20b714a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.",
                "category": "company",
                "datetime": 1785316800,
                "headline": "Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet."
              },
              {
                "id": 141055216,
                "url": "https://finnhub.io/api/news?id=966a4db521a38f4bd8362cfa438d4faa1847fcf076dd360a206963bd600a1816",
                "image": "https://image.cnbcfm.com/api/v1/image/108283570-17745429042026-03-26t163339z_1972272553_rc2dcka2eeqm_rtrmadp_0_novo-nordisk.jpeg?v=1774542953&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.",
                "category": "company",
                "datetime": 1785316279,
                "headline": "Why shareholders are suing Novo Nordisk over next-generation weight-loss drug"
              },
              {
                "id": 141053739,
                "url": "https://finnhub.io/api/news?id=fbc14fcf2674f54b6c7a3ee38c28dcaac0b5ace8e5df1ce63b05e8bc58a72c95",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Jim-Cramer.png?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Jim Cramer likes Ross Stores (ROST) on CNBC's Mad Money Lightning Round. Ross Stores reported strong earnings and raised guidance. Arista Networks (ANET) is also favored.",
                "category": "company",
                "datetime": 1785312779,
                "headline": "Jim Cramer: Arista Is ‘Terrific,’ Also Likes This Consumer Cyclical Stock"
              },
              {
                "id": 141048281,
                "url": "https://finnhub.io/api/news?id=9a0a95dd4dd82e3947e5b235fdaee5bee14eafe1fc4e1863b57c79cde93d8e29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.",
                "category": "company",
                "datetime": 1785275102,
                "headline": "Eli Lilly (LLY) Rises Higher Than Market: Key Facts"
              },
              {
                "id": 141047303,
                "url": "https://finnhub.io/api/news?id=556426890a3fac26e5447912eb362cc02010df281b0dcb32f90c4409a7a36c9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.",
                "category": "company",
                "datetime": 1785271965,
                "headline": "What Johnson & Johnson Stock Told You Before It Surged"
              },
              {
                "id": 141047304,
                "url": "https://finnhub.io/api/news?id=964cb7fb943f3d27b92bfa4cd03543b70ad5d97017a3e0c9b5c997db08924eeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.",
                "category": "company",
                "datetime": 1785271282,
                "headline": "Does Eli Lilly Stock Actually Diversify Your Portfolio?"
              },
              {
                "id": 141045188,
                "url": "https://finnhub.io/api/news?id=9b51439141c29da15f6773f0c3e11b7989e81beaf05eadbc1aee88f09c1c18eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.",
                "category": "company",
                "datetime": 1785256800,
                "headline": "INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised"
              },
              {
                "id": 141045189,
                "url": "https://finnhub.io/api/news?id=c65520ebec3ce3f0bdd7582b5db66f5e2d448347abf3103074d5cb7877b248ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The company isn't resting on its laurels.",
                "category": "company",
                "datetime": 1785256500,
                "headline": "Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs"
              },
              {
                "id": 141045190,
                "url": "https://finnhub.io/api/news?id=735a43ba3d19c4d05c735bc52ebace2e3812b9e0acdf5d504798b0860483b6e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.",
                "category": "company",
                "datetime": 1785251880,
                "headline": "Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings"
              },
              {
                "id": 141041257,
                "url": "https://finnhub.io/api/news?id=7e860275f31851a3380c6be69d64af1696b43a394fa503864f00c0dead7577a6",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Discover how the Best Dividend Stocks screen finds high-quality dividend payers like Eli Lilly (LLY) with sustainable growth, strong profitability, and healthy financials despite a low yield.",
                "category": "company",
                "datetime": 1785233444,
                "headline": "Eli Lilly (NYSE:LLY): A Quality Dividend Stock with Sustainable Growth and Strong Fundamentals"
              },
              {
                "id": 141037134,
                "url": "https://finnhub.io/api/news?id=aeff0d6def877a379e795b7dffbade36bd9049861d9f6cfb0f46760c07b0e388",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.",
                "category": "company",
                "datetime": 1785184622,
                "headline": "3 Quality Compounders to Own for Decades"
              },
              {
                "id": 141037135,
                "url": "https://finnhub.io/api/news?id=f039384443066be35bc6ced345a619fa1e6911431bbd02d74d2a8573ae541097",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.",
                "category": "company",
                "datetime": 1785182092,
                "headline": "The Engine Behind ABBV Stock Has Real Parts"
              },
              {
                "id": 141037136,
                "url": "https://finnhub.io/api/news?id=1962630925adf572941ee3d09545871641e85445ce685d06cecba1d3bddbddb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.",
                "category": "company",
                "datetime": 1785180480,
                "headline": "UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch"
              },
              {
                "id": 141036036,
                "url": "https://finnhub.io/api/news?id=af65196ac17f8ab0c7e78f696d4d665e249450d531ea5f10253facd4a98e3a95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Analysts have been lifting Eli Lilly price targets, with recent valuation work for the stock pointing to fair value of US$1,270.37 compared with the prior US$1,243.43 anchor. The shift lines up with a more constructive Wall Street stance as firms reassess the obesity and diabetes portfolio, retatrutide data, and Q2 earnings setup, with bullish targets clustering between roughly US$1,232 and US$1,600. Ahead, you will see how this evolving narrative, both bullish and cautious, can shape how you...",
                "category": "company",
                "datetime": 1785179297,
                "headline": "Eli Lilly (LLY) Stock Gets Fair Value Bump As Analysts Lift Targets On GLP1 Outlook"
              },
              {
                "id": 141036037,
                "url": "https://finnhub.io/api/news?id=2cc61cdbabe57465c6369f88d1cd57b760ec36da2bc51946d6d2f08f0584f756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.",
                "category": "company",
                "datetime": 1785177225,
                "headline": "Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips"
              },
              {
                "id": 141035101,
                "url": "https://finnhub.io/api/news?id=1030c034e8cbe3e61dd6ad76c34fbb29b759a77e80edf8b047749530be1c2491",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The chief investment strategist at Concurrent Asset Management shares her top investment picks right now.",
                "category": "company",
                "datetime": 1785167040,
                "headline": "Leah Bennett: Where to Invest After the AI-Chip Stock Surge"
              },
              {
                "id": 141032702,
                "url": "https://finnhub.io/api/news?id=69b7ee633481da6f691d2ce0d3a42a7b450ebc2859703f607eb6a2c93ad2b5fb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165541552/image_2165541552.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk (NVO) is rated a Modest Buy with a raised price target of $80, driven by oral Wegovy’s rapid market adoption.",
                "category": "company",
                "datetime": 1785145264,
                "headline": "Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy"
              },
              {
                "id": 141031076,
                "url": "https://finnhub.io/api/news?id=62173fbda2301693a92f3d5da56390b4ea3db8e08c290385b475eabf6e1d5a7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.",
                "category": "company",
                "datetime": 1785135053,
                "headline": "Johnson & Johnson Now Leads Its Pitch With An Oncology Bet"
              },
              {
                "id": 141030812,
                "url": "https://finnhub.io/api/news?id=4b6e6d93296faed73bb2ef8ae9464545cf430aa9aee7768bdfe0f63f83fd0474",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2232218380/image_2232218380.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Veradermics is well-funded through the expected FDA submission in early 2027 and potential commercial launch in 2028. See why MANE stock is a Hold.",
                "category": "company",
                "datetime": 1785119424,
                "headline": "Veradermics: Wait For The Post-Lockup, But Buy Before The Roll-Up"
              },
              {
                "id": 141030025,
                "url": "https://finnhub.io/api/news?id=1dd3cf08ec35aeda44ee0a4ccf7716da4158c17427dfba9ff88325edbfbf3649",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) stock has turned into one of the best comeback trades of 2026. Shares closed at $1,196.03 on July 24, up nearly 11% year to date after a rough start dragged the stock below $900 in the spring. Lilly shares have climbed about 39% since the company's first-quarter report, according to ...",
                "category": "company",
                "datetime": 1785118620,
                "headline": "Goldman Sachs sees writing on the wall for Eli Lilly stock"
              },
              {
                "id": 141016864,
                "url": "https://finnhub.io/api/news?id=02a7054929fccd13b94135fcc42ef9eaf195056dd9ae3898a266d92a88bdf526",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.",
                "category": "company",
                "datetime": 1784989802,
                "headline": "Johnson & Johnson Is Becoming A Narrower Company Than You Bought"
              },
              {
                "id": 141016290,
                "url": "https://finnhub.io/api/news?id=1d19bc20f574b6fd0100ccf29b1d767825b782e2a94c09a145e64e7709d646d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "As AI-related stocks weaken, investors are rotating into other sectors, such as energy and health care.",
                "category": "company",
                "datetime": 1784980828,
                "headline": "Eli Lilly, Dell Among Stocks To Watch As Market Leadership Shifts"
              },
              {
                "id": 141015383,
                "url": "https://finnhub.io/api/news?id=0df2f468b05893397f77694e11a253c45a69ff0ff29dae745e771783104901dd",
                "image": "https://www.chartmill.com/images/uploads/minervini_news_8825971f4b.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) passes Mark Minervini’s Trend Template and High Growth Momentum screen, showing strong technical uptrend, accelerating earnings, rising margins, and positive analyst revisions.",
                "category": "company",
                "datetime": 1784977268,
                "headline": "Eli Lilly (NYSE:LLY): High-Growth Stock with Strong Technical and Fundamental Momentum"
              },
              {
                "id": 141015071,
                "url": "https://finnhub.io/api/news?id=454e8a4f280cf3effa8c4c963d3e8cda968ef07367f04c5ac976cc24420ae9d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk A/S (NYSE:NVO) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday. The firm claimed that Lilly had run misleading advertisements about its weight loss drug when it came to touting their superior performance over Novo Nordisk A/S (NYSE:NVO)’s products. It claimed that Lilly […]",
                "category": "company",
                "datetime": 1784965722,
                "headline": "Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The Courts"
              },
              {
                "id": 141012101,
                "url": "https://finnhub.io/api/news?id=4e1e23cf08396f986f5b9a6bb8cb7b76eaa05c1892763d61ed11183134d2e9c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called \"safer parts of the market.\"\"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well.\"The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.",
                "category": "company",
                "datetime": 1784931586,
                "headline": "Nasdaq lags on angst over AI spending ahead of earnings reports"
              },
              {
                "id": 141009372,
                "url": "https://finnhub.io/api/news?id=f7d003287a3cbb52d7af0f3018775e53fe1e60dbc49c2933f1b91033fc1b2646",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S",
                "category": "company",
                "datetime": 1784921713,
                "headline": "Sector Update: Healthcare Stocks Higher Late Afternoon"
              },
              {
                "id": 141009373,
                "url": "https://finnhub.io/api/news?id=73d13fb54e66cdcbd6b488a4abf3143c4073fe2abe6280be0f2b827aa136fb1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Gene-editing biotech debuts at $25, backed by Sanofi and Eli Lilly, with a roughly $440.3 million valuation.",
                "category": "company",
                "datetime": 1784918719,
                "headline": "Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO"
              },
              {
                "id": 141009374,
                "url": "https://finnhub.io/api/news?id=f29079cb93fdaadf51e53777213d19da17954196751cfd5ad6709e1403cb4756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.",
                "category": "company",
                "datetime": 1784917920,
                "headline": "Eli Lilly and Novo Nordisk Are Locked in a Legal War. Don’t Lose Sight of the Main Event."
              },
              {
                "id": 141007614,
                "url": "https://finnhub.io/api/news?id=82bfef290b7eb689c94507963487a87b5153ed054f02025556ac62c9c7912e74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying opportunity or a trap.",
                "category": "company",
                "datetime": 1784914236,
                "headline": "This Catalyst Makes Eli Lilly a Top Growth Stock in 2026"
              },
              {
                "id": 141007617,
                "url": "https://finnhub.io/api/news?id=6951b5f355a73c081e90627223329c71aa934068bd8231d1e60447efadbeca7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.",
                "category": "company",
                "datetime": 1784913600,
                "headline": "Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?"
              },
              {
                "id": 141007722,
                "url": "https://finnhub.io/api/news?id=05359fd846b18d89b8c59325c07fc0a31ad666ac375b13e38f15f74ac2c22996",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk (CPSE:NOVO B) has filed a federal lawsuit against Eli Lilly over alleged false and misleading advertising of GLP-1 obesity and diabetes drugs. The company argues that Eli Lilly’s ads misrepresent clinical comparisons and risk misleading consumers and healthcare professionals. The case highlights rising tensions as both companies compete in the fast growing market for GLP-1 based obesity and diabetes treatments. Novo Nordisk is a major player in diabetes and obesity treatments,...",
                "category": "company",
                "datetime": 1784912966,
                "headline": "Novo Nordisk (CPSE:NOVO B) Sues Eli Lilly Over GLP 1 Drug Advertising"
              },
              {
                "id": 141007723,
                "url": "https://finnhub.io/api/news?id=180dcd175a3b8d63fc74c5a5b0f746412d4d2b7828b7025b877ea3c73e998f55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.Most Read from BloombergRetina Chip Designed to Restore Sight to Go on Sale in EuropeHegseth Turns to UNC, Virginia Tech After Dropping Ivy LeagueApple Plans Overhaul of MacBooks, iMac in Push to Meet AI DemandTrump Rebuilds Tariffs With New Levies on 60 EconomiesSpaceX Turns Away Falcon Customers in Majo",
                "category": "company",
                "datetime": 1784908426,
                "headline": "Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO"
              },
              {
                "id": 141007724,
                "url": "https://finnhub.io/api/news?id=81bb7ea514d82b3b1d4e151d63f618ce24d24855f6fccfa8074415c723f21ff8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock hit an all-time high of 1,249.50 before pulling back into a buy zone above a pivot of 1,133.95.",
                "category": "company",
                "datetime": 1784907631,
                "headline": "Eli Lilly Stock In A Buy Zone, Set To Ride The Peptide Wave"
              },
              {
                "id": 141007725,
                "url": "https://finnhub.io/api/news?id=95ba08825f92a3e72d114ff1c528c911d6feb9937674c96dd853a9a6490b4e01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Updates with responses from Novo Nordisk and Eli Lilly in the fourth and fifth paragraphs.) Novo",
                "category": "company",
                "datetime": 1784907452,
                "headline": "Update: Market Chatter: Novo Nordisk Seeks Immediate Court Order Against Lilly's Weight-Loss Drug Ads"
              },
              {
                "id": 141007726,
                "url": "https://finnhub.io/api/news?id=05aeb953d4a880fc4fda1e7fcea9049fded33c60c04eb95d11f61b77c46633f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.",
                "category": "company",
                "datetime": 1784903880,
                "headline": "Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?"
              },
              {
                "id": 141006407,
                "url": "https://finnhub.io/api/news?id=5133a22afd0bb5dc4b8f2de4cd583d8b8bc272d15f91e02fce505add9799cc96",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs. The ads compare Lilly’s Zepbound with Novo’s Wegovy, and Novo argues they give consumers a misleading picture of how the blockbuster weight-loss drugs stack up. At the center of ...",
                "category": "company",
                "datetime": 1784903820,
                "headline": "Ozempic maker takes biggest rival to court over weight-loss drug ads"
              },
              {
                "id": 141007727,
                "url": "https://finnhub.io/api/news?id=0774621f2b0c9a53a0f62ac868179d7840bd7b6ab53c6ac9841d1f54f44aa6be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.",
                "category": "company",
                "datetime": 1784902380,
                "headline": "LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins"
              },
              {
                "id": 141006408,
                "url": "https://finnhub.io/api/news?id=b6f9707bc9f6ed2219d0deaed102d5da6173221e5c1c413a16ee4917699e559a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.",
                "category": "company",
                "datetime": 1784902200,
                "headline": "As Eli Lilly and Novo Clash in Court, Wall Street Eyes This Bigger Prize"
              },
              {
                "id": 141005264,
                "url": "https://finnhub.io/api/news?id=32cb2218a67a328b322b36930d9638efeb5443aaf841df708109cda9ea5b35a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.",
                "category": "company",
                "datetime": 1784898540,
                "headline": "As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize"
              },
              {
                "id": 141005265,
                "url": "https://finnhub.io/api/news?id=ff30d3f0dcb8cfe64c581dca1f5ebc3164b165ec416ba23e9fb0887b74eaf602",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Strong demand helps the Lilly-backed biotech raise nearly $129 million",
                "category": "company",
                "datetime": 1784896758,
                "headline": "Lilly-Backed Scribe Prices Upsized IPO"
              },
              {
                "id": 141005266,
                "url": "https://finnhub.io/api/news?id=b68b6a8e7e8f802d753b592c3a557b813211d34ea09ef4ad12c67047a4bc82a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Danish drugmaker alleges Lilly's advertising misrepresents comparisons between rival obesity treatments.",
                "category": "company",
                "datetime": 1784896280,
                "headline": "Novo Nordisk Seeks Injunction Against Eli Lilly Weight-Loss Ads"
              },
              {
                "id": 141005267,
                "url": "https://finnhub.io/api/news?id=29b09d88b6b7378b860e517ec49be6b3ff3adf564dabf4382b4ceb12330e3603",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo says Lilly's ads for Zepbound and Mounjaro rely on outdated data and omit newer, higher-dose versions of Wegovy and Ozempic",
                "category": "company",
                "datetime": 1784894193,
                "headline": "Novo Nordisk seeks injunction to block Eli Lilly weight loss drug ads"
              },
              {
                "id": 141005268,
                "url": "https://finnhub.io/api/news?id=b34b11d0ab9a053674523fb8b459399ccfde76afb9d8c7e9c7598826b1e74e32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Friday’s preliminary injunction request escalates legal proceedings initiated earlier this week.",
                "category": "company",
                "datetime": 1784890260,
                "headline": "Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads"
              },
              {
                "id": 141005269,
                "url": "https://finnhub.io/api/news?id=965663393a8175ecef5a4ebd841f35ce6cb26ff379c81d202eabff42909680fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Lilly’s advertisements for Zepbound and Mounjaro, according to a Reuters report on Friday.",
                "category": "company",
                "datetime": 1784890216,
                "headline": "Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly – Even As Analysts See LLY Leading The GLP-1 Race"
              },
              {
                "id": 141004421,
                "url": "https://finnhub.io/api/news?id=b46414c0af79f2405e8c037b3ea3a1cba81c0d5853dc3ef0a63e3d181c08035c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk (NYSE:NVO) has asked a U. S.",
                "category": "company",
                "datetime": 1784889502,
                "headline": "Novo Nordisk seeks court order to halt Eli Lilly weight-loss drug advertisements"
              },
              {
                "id": 141005270,
                "url": "https://finnhub.io/api/news?id=c37fcb57a93e9cf04821618765f9d298469bfd4bd9775c13dcb0cb7c50d1ccb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs.",
                "category": "company",
                "datetime": 1784885506,
                "headline": "Lilly’s leap into psychedelics; peptides in the spotlight"
              },
              {
                "id": 141006409,
                "url": "https://finnhub.io/api/news?id=e1ce78c5a51a944eb62e6a59e63cc3b2a92e6e9f3dc15efba3b36dc07aba88e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.",
                "category": "company",
                "datetime": 1784883600,
                "headline": "Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma"
              },
              {
                "id": 141009067,
                "url": "https://finnhub.io/api/news?id=3ff15c8b496a2221f5d46eaa53aabd6d7e0def1ef39114f24a3d87a67fb5a568",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.aboutamazon.com/news/devices/new-alexa-top-features",
                "category": "company",
                "datetime": 1784873290,
                "headline": "The Wall Street Journal Reported Earlier, Novo Nordisk Filed Preliminary Injunction Request In U.S. Court To Halt Eli Lilly GLP-1 Weight-Loss Drug Advertising During Lawsuit Proceedings"
              },
              {
                "id": 141002709,
                "url": "https://finnhub.io/api/news?id=4690c8bceee94a7bc498375f5c6b1872f0e58b125bf0ab5029987042be36e37a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "There are plenty of reasons to love these companies.",
                "category": "company",
                "datetime": 1784868600,
                "headline": "2 Top Growth Stocks to Buy Right Now Without Any Hesitation"
              },
              {
                "id": 140997601,
                "url": "https://finnhub.io/api/news?id=9a7c5197d026eae722976256cb490cd81623c46e49ec64717db7313e4a8094ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.",
                "category": "company",
                "datetime": 1784830680,
                "headline": "Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum"
              },
              {
                "id": 140997602,
                "url": "https://finnhub.io/api/news?id=dcb90ca8738804304b4720e09b8a9a9fe7682c5918c5e1fb3833f6ce4674848b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.",
                "category": "company",
                "datetime": 1784828301,
                "headline": "There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders"
              },
              {
                "id": 140997603,
                "url": "https://finnhub.io/api/news?id=8aaf90a0055946157928aaaa976b080f50916599f7ffcba9609c4e9fab0a4b4c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Two more Phase 3 trials showed weight loss above 20%",
                "category": "company",
                "datetime": 1784826801,
                "headline": "Lilly Targets Early 2027 Filing for Next Obesity Drug"
              },
              {
                "id": 140997604,
                "url": "https://finnhub.io/api/news?id=7b9d30d4c4091626ac26fbb2dc3e80caa5201f491007b479a434b4b5af03ce3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Retatrutide delivered substantial weight loss in two additional late-stage trials.",
                "category": "company",
                "datetime": 1784826645,
                "headline": "Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing"
              },
              {
                "id": 140997605,
                "url": "https://finnhub.io/api/news?id=7e5d80e67c6d1a9459c3bce7668de08472da0c3ae72ce8de417b55033c38e8c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Drugmaker  Eli Lilly  said Thursday that it is on track to seek federal approval for its next-generation obesity drug early next year.  Lilly became the first drug company to reach a trillion dollar valuation last fall as sales of its weight loss drugs took off.  Among adults with general obesity, the weekly injectable lowered the weight of late-stage trial participants by an average of 28% over 80 weeks at the highest doses tested.",
                "category": "company",
                "datetime": 1784823840,
                "headline": "Lilly Stock Is Rising on Plan to Seek Approval for Newest Weight-Loss Drug in 2027"
              },
              {
                "id": 140994623,
                "url": "https://finnhub.io/api/news?id=d16681bea87a6c620037072934ddd19c62b77d701ddb423dc87133e19ef199ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investing.com -- Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The pharmaceutical company said it needs additional time to collect and verify manufacturing and quality-control data required by regulators.",
                "category": "company",
                "datetime": 1784820163,
                "headline": "Lilly to file for next-gen obesity drug approval in early 2027"
              },
              {
                "id": 140994624,
                "url": "https://finnhub.io/api/news?id=a128be632149988299adc1fe9cacb82f55defe5853819b35c97ee3dee9932d42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly’s nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo’s Wegovy and Ozempic. The case raises legal and regulatory questions around drug marketing practices in the high-stakes GLP-1 market, where only a few companies currently compete at scale. Beyond the courtroom, this dispute highlights...",
                "category": "company",
                "datetime": 1784819722,
                "headline": "How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story"
              },
              {
                "id": 140994625,
                "url": "https://finnhub.io/api/news?id=86ea9dd4ef833438bd7fe5e9ffe85939adc80cda913f0390326517f45bf4d02d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "If approved, Lilly’s triple-g agonist would become the company’s fifth glucagon-based drug to be marketed.",
                "category": "company",
                "datetime": 1784817738,
                "headline": "Another win for Lilly’s triple-g agonist in two more Phase III trials"
              },
              {
                "id": 140994626,
                "url": "https://finnhub.io/api/news?id=22df39746c7745426510628b0dd3e7976822ef0451fff3c063ba6b93d5addb6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.",
                "category": "company",
                "datetime": 1784815920,
                "headline": "How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?"
              },
              {
                "id": 140996690,
                "url": "https://finnhub.io/api/news?id=85af9e8893acc6773c696c8ffbce2fa38f27f38ee6fd643adf77b9f3130959f1",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1784813736,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140993199,
                "url": "https://finnhub.io/api/news?id=1e1dcde38b10d200c988610b782f0e840f7cf8f05ba9c867262a78abb2f4d942",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.",
                "category": "company",
                "datetime": 1784811900,
                "headline": "Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know."
              },
              {
                "id": 140993327,
                "url": "https://finnhub.io/api/news?id=cc7eb5954b2304db65d535608c2266717c11c4d3d15590a1c8a922bcbd5bdac9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Retatrutide, a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, met the primary endpoint in both the Triumph-2 and Triumph-3 Phase 3 studies.",
                "category": "company",
                "datetime": 1784809395,
                "headline": "Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing"
              },
              {
                "id": 140994627,
                "url": "https://finnhub.io/api/news?id=79dd45d94c59a069cd283e39bad622b0a875c167db9522f4bc04cf6e1ee8e544",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.",
                "category": "company",
                "datetime": 1784806895,
                "headline": "Lilly, with new data, to seek FDA approval of obesity drug retatrutide"
              },
              {
                "id": 140993328,
                "url": "https://finnhub.io/api/news?id=6823179c17dba300c1c40589f478e730f416a20cb6cb32b0e76fa68c52c5cb64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.",
                "category": "company",
                "datetime": 1784803680,
                "headline": "Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data"
              },
              {
                "id": 140992499,
                "url": "https://finnhub.io/api/news?id=e45b55ad179ab6476d3c8b30b375a2d7cd90f26a20784c8a863bac2b1f401ca9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some of its most serious complications: type 2 diabetes and establis",
                "category": "company",
                "datetime": 1784803500,
                "headline": "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C"
              },
              {
                "id": 140991785,
                "url": "https://finnhub.io/api/news?id=a78be83fdf06a774980bf42e0ece428594a4d4dc39e9c1bc1738bddae85cff76",
                "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) shows strong growth with 113% EPS growth and a bullish technical breakout setup, earning 9/10 ratings for both fundamentals and chart pattern.",
                "category": "company",
                "datetime": 1784799630,
                "headline": "Eli Lilly (NYSE:LLY) Shows Strong Growth and Breakout Technical Setup"
              },
              {
                "id": 140996713,
                "url": "https://finnhub.io/api/news?id=ffba3497dd1ecae3d5b31c52d08ca5f1c925c7328701553b9ae8fae28647e3bb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/23/Eli-Lilly.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly reports positive Phase 3 data for retatrutide, showing major weight loss in adults. US regulatory submission is planned for 2027.",
                "category": "company",
                "datetime": 1784797207,
                "headline": "Eli Lilly Says Retatrutide Shows Cardiovascular, Diabetic Benefits"
              },
              {
                "id": 140995857,
                "url": "https://finnhub.io/api/news?id=948af664a91f1ed7d0e8f105167e55fa50b154364931d9f703d70f73a6ac3559",
                "image": "https://image.cnbcfm.com/api/v1/image/108330310-1783027295728-gettyimages-2284381414-_m0a2793_xi38wxwr.jpeg?v=1783027486&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1784792063,
                "headline": "Stocks making the biggest moves premarket: Lockheed Martin, Tesla, Alphabet & more"
              },
              {
                "id": 140996714,
                "url": "https://finnhub.io/api/news?id=e4437449a4ed459de0cf3a1486f7943e1ec99f5632f30cf520c7a1c8b6a64a7c",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating",
                "category": "company",
                "datetime": 1784789311,
                "headline": "Eli Lilly Reports Topline Results From TRIUMPH-2 And TRIUMPH-3 Phase 3 Trials Evaluating Retatrutide; Treatment Met Primary Endpoint, With Substantial Weight Loss In Adults With Obesity"
              },
              {
                "id": 140995874,
                "url": "https://finnhub.io/api/news?id=e83cb9df1fdd4022d376515ac192a92b16cfbc1d774c5b7524b0b2f824fe1cd7",
                "image": "https://image.cnbcfm.com/api/v1/image/108230176-1764603822722-108230176-17637559702025-11-21t201158z_1546648356_rc261iafo6zz_rtrmadp_0_lilly-stocks.jpg?v=1779898152&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.",
                "category": "company",
                "datetime": 1784789102,
                "headline": "Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials"
              },
              {
                "id": 140991356,
                "url": "https://finnhub.io/api/news?id=4d840276aeb0d6f1dfb2fa943380324e66e059bacf6629b0c8603290a23fb52d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]",
                "category": "company",
                "datetime": 1784787517,
                "headline": "Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline"
              },
              {
                "id": 140997606,
                "url": "https://finnhub.io/api/news?id=ce69505dde9c2aa7483984a1a158e4307eff9fe773f140fbefc671155f13219d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Generic drugmakers have much thinner margins, and are less interested in “reshoring” to the US where the costs are higher.",
                "category": "company",
                "datetime": 1784779260,
                "headline": "Trump’s 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts"
              },
              {
                "id": 140984714,
                "url": "https://finnhub.io/api/news?id=bd326c72d5b48fc9d87d6488a1fdb496e6a1b97eafbc9571a0ac45ae8cb1bbd7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the wrong direction for Novo. Here is what the stock reaction reveals about who is actually winning this war.",
                "category": "company",
                "datetime": 1784737521,
                "headline": "The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side"
              },
              {
                "id": 140983019,
                "url": "https://finnhub.io/api/news?id=c3c43c401f44116db2170f2c44b2f94a1c0eaf7be37797d8b20b550f6d4aed9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.",
                "category": "company",
                "datetime": 1784731320,
                "headline": "NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now"
              },
              {
                "id": 140983020,
                "url": "https://finnhub.io/api/news?id=17e5f2ca7d54253b692081f105ffa61e3c91f2aa5224d83d41d26dc1977763f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's expanding GLP-1 portfolio and pipeline remain in focus as demand stays strong ahead of its second-quarter earnings results.",
                "category": "company",
                "datetime": 1784730180,
                "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Costco Wholesale, Morgan Stanley and Kewaunee Scientific"
              },
              {
                "id": 140983021,
                "url": "https://finnhub.io/api/news?id=a6f7d48efa7ce55737dec470f4e6523b6d251d05fec3840ffe8d744b0cbe11b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
                "category": "company",
                "datetime": 1784728800,
                "headline": "Lilly confirms date and conference call for second-quarter 2026 financial results announcement"
              },
              {
                "id": 140983022,
                "url": "https://finnhub.io/api/news?id=c4fa2481b4dffac5d9a26a33c9dc996570ab15065375f16241046649efd8ada1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, with a third study set to start in September. Shares rise.",
                "category": "company",
                "datetime": 1784728320,
                "headline": "NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis"
              },
              {
                "id": 140981764,
                "url": "https://finnhub.io/api/news?id=fe4752d3fa507f1a71bb2fbc30af30104fbf8a525645ed5a3e73ad0ec80ed866",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.",
                "category": "company",
                "datetime": 1784726247,
                "headline": "LLY Has Momentum. The Question Is The Price"
              },
              {
                "id": 140986284,
                "url": "https://finnhub.io/api/news?id=b2972b986cf129ebe0edfdde09e818d798a762dbd2019e1a121090c7ee499dfb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.",
                "category": "company",
                "datetime": 1784723911,
                "headline": "What You Need to Know Ahead of Eli Lilly's Earnings Release"
              },
              {
                "id": 140983761,
                "url": "https://finnhub.io/api/news?id=96be1c9a57931cb47d1e6d9d1241589e4644addd7b819db5dfae61b589c0610f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340690121/image_1340690121.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Seagate Technology shares continued to advance as demand for high-capacity storage tied to AI data-center buildouts supported further positive earnings revisions.",
                "category": "company",
                "datetime": 1784723700,
                "headline": "Nomura Core Equity Fund Q2 2026 Portfolio Review"
              },
              {
                "id": 140980884,
                "url": "https://finnhub.io/api/news?id=856013786cfee49180836033d17881b78a32c41bd368c8856e103108e23f0a3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Jim Cramer is sounding the alarm for investors still riding the AI wave, and his warning carries a specific body count. Here is where he says the smart money is quietly moving before the damage hits.",
                "category": "company",
                "datetime": 1784715732,
                "headline": "“If You Own Too Much Tech, You’re Going To Be Slaughtered.” Cramer Urges Investors To Take Profits"
              },
              {
                "id": 140980977,
                "url": "https://finnhub.io/api/news?id=7a6528725d9c46a032b9aec4860fb2d1d0620a931ee06da19f7676b4d8235c80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CHICAGO, July 22, 2026--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in \"Hallucinating Value: Healthcare's AI Narrative.\"",
                "category": "company",
                "datetime": 1784714400,
                "headline": "Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown"
              },
              {
                "id": 140981530,
                "url": "https://finnhub.io/api/news?id=6b6018e5672410183893a1ef8edd7db31fdb8f487a6c07dee7f72e0f18122db2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2283703169/image_2283703169.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novartis AG ended Q2 on a high note as oncology offset Entresto weakness; 2026 guidance reaffirmed. Read why NVS stock is upgraded to a buy.",
                "category": "company",
                "datetime": 1784712513,
                "headline": "Novartis: The Buy Thesis Is Back (Rating Upgrade)"
              },
              {
                "id": 140980672,
                "url": "https://finnhub.io/api/news?id=50b58c922e0c9aa926f433602a29e8525b738056a0af77e107d9574d4d195a28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1828680033/image_1828680033.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Super Micro rockets higher. The clock is ticking for generic drug imports. Nike's China strategy shift.",
                "category": "company",
                "datetime": 1784703600,
                "headline": "Wall Street Breakfast Podcast: Super Micro Heats Up"
              },
              {
                "id": 140984715,
                "url": "https://finnhub.io/api/news?id=69b3009beac273383d7deed0ef8929b415ffa5502aa6bbc8db8f10fdded798f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Danish pharma giant alleged Lilly misled consumers with false advertising claims that its weight loss drug is superior to Novo’s.",
                "category": "company",
                "datetime": 1784692860,
                "headline": "Novo Nordisk Takes Rival Eli Lilly to Court Over Weight-Loss Ad Claims"
              },
              {
                "id": 140977644,
                "url": "https://finnhub.io/api/news?id=4218cab00fc1d9a327129391ab2f1b3d97a54d46c0db770e5c6cc09f29353025",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk’s lawsuit against Eli Lilly (LLY) over alleged misleading GLP-1 advertising has put fresh attention on Lilly’s stock and raised questions about how core obesity and diabetes franchises are being marketed. See our latest analysis for Eli Lilly. Against this legal backdrop, Eli Lilly’s 1-day share price return of 2.49% and 30-day share price return of 6.99% sit within a broader upswing, with a 52.46% 1-year total shareholder return and a very large 5-year total shareholder return...",
                "category": "company",
                "datetime": 1784675656,
                "headline": "Is Eli Lilly (LLY) Undervalued After Novo Nordisk’s GLP 1 Advertising Lawsuit?"
              },
              {
                "id": 140977645,
                "url": "https://finnhub.io/api/news?id=2f7b4f601dcf7f7dd0037826b05db3c67ac340ce3f2b40cb72795ee87c41e6af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk stock has had a tough stretch over the past few years, yet current valuation checks suggest the market may now be pricing it more cautiously than the fundamentals imply. Over the past 3 years, Novo Nordisk has delivered a total shareholder return that is down 35.8%, which puts the recent share price in the context of a material drawdown for long term holders. Expectations around the obesity and diabetes franchise, including products such as Wegovy, sit alongside legal and...",
                "category": "company",
                "datetime": 1784672152,
                "headline": "Novo Nordisk (CPSE:NOVO B) Stock Looks Reasonable On Earnings While Returns Stay Weak"
              },
              {
                "id": 140976254,
                "url": "https://finnhub.io/api/news?id=d312544c2126879586c6f841dd51947659f186109d11c9e56902a50eb9c0ea81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.",
                "category": "company",
                "datetime": 1784670841,
                "headline": "\"Deceptive Advertising!\" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks."
              },
              {
                "id": 140976347,
                "url": "https://finnhub.io/api/news?id=2d7dd2b1278139b412662c287ad311d6d5433b1ffa75133d854ac78f9065fe62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The weight-loss drug wars reached a new level of intensity Tuesday as Novo Nordisk sued Eli Lilly , accusing its arch-rival of misleading advertising.",
                "category": "company",
                "datetime": 1784669115,
                "headline": "Novo accuses rival Eli Lilly of \"deceptive\" weight-loss drug ads"
              },
              {
                "id": 140976348,
                "url": "https://finnhub.io/api/news?id=a56eb6977a8dbdf25a1c0af3adf0fdb78a9d0a5fa51fe905fa0d496203557c7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's GLP-1 portfolio, pipeline progress and 2026 acquisitions are driving growth despite pricing pressure and rising competition.",
                "category": "company",
                "datetime": 1784664300,
                "headline": "Top Research Reports for Eli Lilly, Costco & Morgan Stanley"
              },
              {
                "id": 140976349,
                "url": "https://finnhub.io/api/news?id=82d9525d03dbe9eedcd561c6aff3946e429bd9bd996312bd1f19747ca485afce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.",
                "category": "company",
                "datetime": 1784664282,
                "headline": "Eli Lilly Stock And The Price Of Confidence"
              },
              {
                "id": 140974895,
                "url": "https://finnhub.io/api/news?id=1ac5caa10a21ca147aa3006cba72e0bc0f153d7e70b3a4dc4eb91f33349c26f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the",
                "category": "company",
                "datetime": 1784662859,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 140974896,
                "url": "https://finnhub.io/api/news?id=db6cdd51ed994892da17837a3314c0ba5404d44f284cc0305ce2609a9abb9653",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "STORY: :: Novo Nordisk claims misleading ads in Eli Lilly weight-loss drug lawsuit:: July 21, 2026:: Maggie Fick, European Pharma Industry Correspondent\"Novo Nordisk sued rival Eli Lilly in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising and claiming its weight-loss medicines outperform Novo's drugs.\" //\"Novo is alleging in its suit that Lilly's advertisements compare weight-loss results of about 50 pounds for its drug Zepbound with about 33 pounds for Wegovy, even though no head-to-head clinical trial has compared the highest approved doses of the medicines.\"\"Pharmaceutical companies regularly sue each other over claims related to patent infringement, for example, but false advertising suits, such as the one filed today, are less common.\"\"Novo Nordisk was first to market with its weight-loss injection Wegovy several years ago, but it later lost the lead to Eli Lilly, after that company launched a rival injection called Zepbound in the United States. Last year, Novo replaced its CEO and was forced to issue multiple profit warnings as it fell further behind Eli Lilly in this really competitive and booming obesity drug market, which analysts expect to be worth more than $100 billion by 2030. This year, Novo has actually sort of landed a counterpunch with its oral Wegovy pill. It was able to launch that drug ahead of Eli Lilly. Lilly has, in April, launched its own pill, a weight-loss pill. But Novo has managed to keep up strong sales even since the launch of Lilly's pill.\"\"Both companies report quarterly results in the next couple of weeks.\":: Novo Nordisk:: Eli LillyThe Danish company filed the lawsuit in U.S. District Court ‌in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo's Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.But Indianapolis-based Eli Lilly said it stands firmly behind its ads, which are based on the results of its SURMOUNT-5 trial. That ⁠trial — completed in 2024 — compared patients on 10 mg or 15 mg of Lilly's Zepbound to patients on 1.7 mg or 2.4 mg doses of Wegovy. The FDA approved ​a 7.2 mg dose of Wegovy in March of this year.",
                "category": "company",
                "datetime": 1784660210,
                "headline": "Novo sues Lilly, claiming misleading ads in weight-loss drug battle"
              },
              {
                "id": 140974897,
                "url": "https://finnhub.io/api/news?id=4527046ec46f67e07022ec64ce36d30476070db35309a16067f492a6176d2f66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.",
                "category": "company",
                "datetime": 1784658705,
                "headline": "AbbVie Stock Zigs When The Market Zags"
              },
              {
                "id": 140973254,
                "url": "https://finnhub.io/api/news?id=7cca9487422533579c49e732eec72b53588140d7206136df59fb6cb6c55fb443",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.4% and the",
                "category": "company",
                "datetime": 1784654979,
                "headline": "Sector Update: Healthcare Stocks Advance Tuesday Afternoon"
              },
              {
                "id": 140973255,
                "url": "https://finnhub.io/api/news?id=aeef7ea0bf4b894c0a43a6d095635fa719538fec9a31edf51e60bd2511684e6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged \"misleading\" adverti",
                "category": "company",
                "datetime": 1784652076,
                "headline": "Novo Nordisk Sues Eli Lilly Over Alleged 'Misleading' Ad Campaigns"
              },
              {
                "id": 140973256,
                "url": "https://finnhub.io/api/news?id=29abcc8d0e94596aa56202324ee49811dd698588001a65834e415155cce0c1f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In a lawsuit filed in the US, Novo alleged that Lilly’s campaign was designed to mislead consumers on “comparative efficacy” of drug brands.",
                "category": "company",
                "datetime": 1784650954,
                "headline": "Novo sues Lilly after alleged misleading and false advertising campaign"
              },
              {
                "id": 140973257,
                "url": "https://finnhub.io/api/news?id=905818d80fb6e3574711e60f78c49f15c8476f086ace982f0077aec934669ff8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Updates with Eli Lilly's response in the fifth and sixth paragraphs.) Novo Nordisk (NVO) said Tu",
                "category": "company",
                "datetime": 1784650610,
                "headline": "Update: Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Advertising"
              },
              {
                "id": 140973258,
                "url": "https://finnhub.io/api/news?id=f28be650fad11e9188136404e95cbffcab5b25d4d2692a379e454692be8b6907",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The European markets closed higher Tuesday as tech, bank, and mining stocks rallied, while investors",
                "category": "company",
                "datetime": 1784649329,
                "headline": "European Stocks Close Higher in Tuesday Trading; Investors Await ECB Rate Decision"
              },
              {
                "id": 140973259,
                "url": "https://finnhub.io/api/news?id=93053a6dafdc3936b236bd0d8c08abe9a30a83776cd88812bb68f6b6d7ce6d71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 per share while the index has gained 8.4%.",
                "category": "company",
                "datetime": 1784649026,
                "headline": "Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140971564,
                "url": "https://finnhub.io/api/news?id=1bf4a57be3dd22914964e340811aa40d739283a736d914beccd336aa57b7e604",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "All three major US stock indexes were up in late-morning trading Tuesday, as investors focused on so",
                "category": "company",
                "datetime": 1784648948,
                "headline": "Top Midday Stories: 3M Shares Rise on Strong Guidance; Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising"
              },
              {
                "id": 140971565,
                "url": "https://finnhub.io/api/news?id=53dcca44de39d5d13badd71f5cd9329b9f05fe72a89744eca707919c05e2d8d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Danish drugmaker alleges Lilly used outdated trial data to claim Zepbound beats Wegovy on weight loss",
                "category": "company",
                "datetime": 1784648036,
                "headline": "Novo Sues Lilly Over Weight-Loss Ad Claims"
              },
              {
                "id": 140971566,
                "url": "https://finnhub.io/api/news?id=65db53db472672696d2d7c3105ced46e7287d590f51bb699fe60ed1a6f1a963f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival’s advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District...",
                "category": "company",
                "datetime": 1784647080,
                "headline": "Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims"
              },
              {
                "id": 140971567,
                "url": "https://finnhub.io/api/news?id=65efb07d7073290eeadfbe8738f5f22b9148c48c2206a9154393113014efd1ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.",
                "category": "company",
                "datetime": 1784644740,
                "headline": "Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know"
              },
              {
                "id": 140971568,
                "url": "https://finnhub.io/api/news?id=250f7bb1c408461b9f8a9a95386cf448cfdd0c8361cb1b37ca741e7574a7b4ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.",
                "category": "company",
                "datetime": 1784644521,
                "headline": "Novo Nordisk sues Eli Lilly, accusing it of false advertising"
              },
              {
                "id": 140971569,
                "url": "https://finnhub.io/api/news?id=5701eb8be606782bc395b4ab1b0885a0b3231ec27c98d93ec8e17f582eababa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.",
                "category": "company",
                "datetime": 1784644140,
                "headline": "Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising"
              },
              {
                "id": 140971570,
                "url": "https://finnhub.io/api/news?id=1c2b2002589f59ce4729d3d6d1b74566f8ad65240e433d0f85304bedcb57fbea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.",
                "category": "company",
                "datetime": 1784643420,
                "headline": "GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk"
              },
              {
                "id": 140971571,
                "url": "https://finnhub.io/api/news?id=5b77ab39182f5f6397ac13467d36a191807a0013444eb2254cf52e9273455cca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk (NVO) is suing Eli Lilly (LLY) for misleading advertising. Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne.",
                "category": "company",
                "datetime": 1784642462,
                "headline": "Weight-loss wars: Why Novo Nordisk is suing Eli Lilly"
              },
              {
                "id": 140971572,
                "url": "https://finnhub.io/api/news?id=aaf4dc4f37d7c1738bb337979f6ad887b695b104a5e86c33f46a813bafc70219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Drugmakers clash over marketing of blockbuster obesity and diabetes treatmentsNovo Nordisk Inc. (NYSE:NVO) has filed a lawsuit against Eli Lilly and Company (NYSE:LLY) and Lilly USA, LLC, accusing its rival of false advertising and unfair competition in a dispute over marketing claims for their leading GLP-1 medicines.",
                "category": "company",
                "datetime": 1784641847,
                "headline": "Novo Nordisk sues Eli Lilly over GLP-1 advertising claims in escalating legal battle (NVO, LLY)"
              },
              {
                "id": 140970419,
                "url": "https://finnhub.io/api/news?id=1d3a98d8166e1d62fe31e1a36ca7e485d7b3b78c5e3ba3536eef57d2d2cefba2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over \"false and materially misleading\" adverts for their competing weight-loss and anti-diabetes treatments. Novo Nordisk has developed a molecule called semaglutide, while Eli Lilly developed rival molecule tirzepatide.",
                "category": "company",
                "datetime": 1784638794,
                "headline": "Pharma heavyweights clash over anti-obesity drug ads"
              },
              {
                "id": 140970420,
                "url": "https://finnhub.io/api/news?id=faef8396042d8c8ca053b4159333a0762ceec68b12fabc099fd567744019bc60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.",
                "category": "company",
                "datetime": 1784638298,
                "headline": "Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro Ads"
              },
              {
                "id": 140972831,
                "url": "https://finnhub.io/api/news?id=9998884f56a979486db43d0796f74bc7aa47567d33055de61814f7a36f6877cb",
                "image": "https://image.cnbcfm.com/api/v1/image/108338007-17846520361784652033-47303621411-1080pnbcnews.jpg?v=1784652035&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "The Investment Committee debate some of their stocks that are moving today.",
                "category": "company",
                "datetime": 1784637874,
                "headline": "Committee stocks on the move: Eli Lilly, D.R. Horton, SpaceX and Live Nation"
              },
              {
                "id": 140970421,
                "url": "https://finnhub.io/api/news?id=03bf594974cadcbdde2a8f7e30526e4e2515e9a990806faeecc9b2fb59fbe453",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act. The lawsuit takes aim at Lilly’s aggressive direct-to-consumer (DTC) advertising campaigns for its blockb",
                "category": "company",
                "datetime": 1784636398,
                "headline": "Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud"
              },
              {
                "id": 140970422,
                "url": "https://finnhub.io/api/news?id=1d8f6535cc184536362666620d37f4fcff10a91ffcee247fd0a2e0271f66c310",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.",
                "category": "company",
                "datetime": 1784635545,
                "headline": "Wegovy maker sues rival Eli Lilly over 'deliberately false' GLP-1 ads"
              },
              {
                "id": 140970423,
                "url": "https://finnhub.io/api/news?id=746aee4cae4e29afaba580b12f048634073e4479976f7b58bf986e5b9d9bfbaf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.",
                "category": "company",
                "datetime": 1784635080,
                "headline": "Novo Nordisk Files Deceptive Advertising Lawsuit Against Rival Eli Lilly"
              },
              {
                "id": 140969462,
                "url": "https://finnhub.io/api/news?id=8997d9a68a10f6e74d8e038102dea334f9ec13c4c35c96be0f36f32a0804fcc7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo says Lilly's TV and social media campaigns cite outdated trial data to make Zepbound and Mounjaro look more effective than rival injections",
                "category": "company",
                "datetime": 1784634723,
                "headline": "Novo Nordisk sues Eli Lilly over misleading weight loss drug ads"
              },
              {
                "id": 140970424,
                "url": "https://finnhub.io/api/news?id=2e6740fd37fcee2c66fbdf6503b2fcc1070ab2f216641494387bf05a556fdbcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly’s advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memor",
                "category": "company",
                "datetime": 1784634626,
                "headline": "Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads"
              },
              {
                "id": 140969463,
                "url": "https://finnhub.io/api/news?id=75302f3772a8070817b6057db89f750a8aaf08892335b4a8a3680860719ec4b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk has accused arch-rival Eli Lilly of peddling false claims about its weight-loss products in advertising campaigns, marking the latest...",
                "category": "company",
                "datetime": 1784633760,
                "headline": "Novo Nordisk accuses Eli Lilly of deceptive marketing in weight-loss fight"
              },
              {
                "id": 140969464,
                "url": "https://finnhub.io/api/news?id=2ff846dfada1566f1e4b24f0b0fbb17b4d2d3bc4fa6a7685221ec97b44e5cc30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies to compare the highest injectable doses of Lilly's medicines against lower doses of Novo Nordisk's injectable medicines for obesity and type 2 diabetesThese high-profile US advertising campaigns create the misleading impression that Lilly’s medicines are superior, including by withholding critical scientific evidence about newer, more effective FDA-",
                "category": "company",
                "datetime": 1784633700,
                "headline": "Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly"
              },
              {
                "id": 140974172,
                "url": "https://finnhub.io/api/news?id=169f8da3bf17dd19ac1abbd97989e1744ef1415c756128b80432a294ab91a7d2",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "- Reuters",
                "category": "company",
                "datetime": 1784630647,
                "headline": "Eli Lilly On Novo Nordisk Lawsuit, Says \"We Stand Firmly Behind Our Advertising\"; We Will Continue To Focus On The Science And Defend Against Novo Nordisk Lawsuit Vigorously; Rather Than Compete On The Merits Of Its Products, Novo Is Asking Court To Stop Lilly From Communicating Results Of That Trial"
              },
              {
                "id": 140974173,
                "url": "https://finnhub.io/api/news?id=784d431219287d39dbb8cc8782acc6178638ee786e997fd2e6da8f627146cb2d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/21/Weight-loss-lawsuits.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments.",
                "category": "company",
                "datetime": 1784629664,
                "headline": "Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising"
              },
              {
                "id": 140972832,
                "url": "https://finnhub.io/api/news?id=5dca2b4f83a7ebe0229170c50319eda255969a6b176d5b5faa61105db3e384af",
                "image": "https://image.cnbcfm.com/api/v1/image/108337893-17846416031784641600-47301177834-1080pnbcnews.jpg?v=1784641602&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1784627937,
                "headline": "Cramer’s Mad Dash: Eli Lilly"
              },
              {
                "id": 140970425,
                "url": "https://finnhub.io/api/news?id=c5d975e3a6da276348f1132772f534ed7900abab4fcf05fcf3aea20d91aefd65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.",
                "category": "company",
                "datetime": 1784625838,
                "headline": "Beyond weight loss: Lilly aims for leadership in brain science"
              },
              {
                "id": 140974174,
                "url": "https://finnhub.io/api/news?id=5dcd15d27947c91a39a943ea845ed7e81570a3a712285a6d814b5f1f30ecdeec",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli LillyA lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses",
                "category": "company",
                "datetime": 1784619742,
                "headline": "Novo Nordisk Takes Legal Action Against Eli Lilly To Stop Multiple Misleading National GLP-1 Advertising Campaigns"
              },
              {
                "id": 140972833,
                "url": "https://finnhub.io/api/news?id=62b38c69da926ad0682e39a7b798688b323e431d8655822360a306de9706c8bb",
                "image": "https://image.cnbcfm.com/api/v1/image/108328219-1782751789876-gettyimages-2279484892-64393_48_ms_4772.jpeg?v=1782751835&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Novo asked the court to permanently stop Lilly from running the \"deceptive\" ads and require the drugmaker to issue corrective advertising.",
                "category": "company",
                "datetime": 1784619346,
                "headline": "Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising"
              },
              {
                "id": 140969465,
                "url": "https://finnhub.io/api/news?id=1b34e6be29cc89ee95fc326d2194f47a17c3e7b5ff5a00519769067076ecd27d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...",
                "category": "company",
                "datetime": 1784606430,
                "headline": "Psychedelic drugs are going mainstream"
              },
              {
                "id": 140966202,
                "url": "https://finnhub.io/api/news?id=3d9813fceba3cf5e2cd0c0d79b98773b1e68786cdc6c96489fa8468aba8b674d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, forming an alliance focused on mapping human disease biology using large-scale genomic data and AI-driven drug discovery. The collaboration aims to build a detailed reference of cellular and genetic information across diseases, supporting the discovery of new drug targets. Eli Lilly enters this alliance with strong recent stock performance, with the share price at $1,146.9 and the stock up 51.5% over the...",
                "category": "company",
                "datetime": 1784585555,
                "headline": "Eli Lilly (LLY) Joins Illumina Atlas To Map Disease With AI"
              },
              {
                "id": 140966203,
                "url": "https://finnhub.io/api/news?id=1452c1869014b6b433e26965f1d74215469d6bc9f3c57b5e9c9eeb36f9d9df9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "President Donald Trump recently praised Eli Lily at a public event and called it “a great company” and highlighted its planned $3.5 billion investment for a manufacturing plant in Pennsylvania. However, Claude AI begs to differ from Trump. The AI agent recently sold its entire stake in Eli Lilly and Company (NYSE:LLY). Claude AI said […]",
                "category": "company",
                "datetime": 1784584968,
                "headline": "Claude AI Disagrees With President Trump on Eli Lilly (LLY)"
              },
              {
                "id": 140966204,
                "url": "https://finnhub.io/api/news?id=7f2c907390b8838692356a0fabec76d8aebd3d9b5dcc83121dc03dd9efc912a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous day.",
                "category": "company",
                "datetime": 1784583906,
                "headline": "Here's Why Eli Lilly (LLY) Fell More Than Broader Market"
              },
              {
                "id": 140964862,
                "url": "https://finnhub.io/api/news?id=c32d8e14612b49c61afd688e00df609f03b2a8d835d88092db70f594f6df9aac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Gene-editing biotech targets up to $242.7 million valuation, with initial ASCVD trial data expected in 2027.",
                "category": "company",
                "datetime": 1784577602,
                "headline": "Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase"
              },
              {
                "id": 140963402,
                "url": "https://finnhub.io/api/news?id=572d40f14f1b492f6e45585c523e13a6ab5e38d1367d2cea2035434ec4089ff2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t",
                "category": "company",
                "datetime": 1784575650,
                "headline": "Sector Update: Healthcare Stocks Fall Late Afternoon"
              },
              {
                "id": 140963403,
                "url": "https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.",
                "category": "company",
                "datetime": 1784573756,
                "headline": "Reading Between The Lines Of JNJ Stock's Latest Call"
              },
              {
                "id": 140963313,
                "url": "https://finnhub.io/api/news?id=a84e85e25284b1b21f06d40715163bf0e20d0344ecae4ab283e99b44fc5db455",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.",
                "category": "company",
                "datetime": 1784572200,
                "headline": "Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?"
              },
              {
                "id": 140962784,
                "url": "https://finnhub.io/api/news?id=1867da7d02812b87cf8dcf301fdaf9d9703a244c1c79a27133b08cd620c401cf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305424/image_2158305424.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk shares have rallied approximately 27%, driven by accelerating commercial momentum behind Oral Wegovy. Read more on NVO stock here.",
                "category": "company",
                "datetime": 1784558856,
                "headline": "Novo Nordisk's Rally Has Room To Run Driven By Oral Wegovy's Momentum"
              },
              {
                "id": 140960592,
                "url": "https://finnhub.io/api/news?id=87bfd39ebb959bc43097f4456ea6b094616b0e6e95837584dbc90e6f99fc6a59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.",
                "category": "company",
                "datetime": 1784555460,
                "headline": "Does EU Approval of Wegovy Pill Change NVO's Competitive Story?"
              },
              {
                "id": 140960593,
                "url": "https://finnhub.io/api/news?id=9bfd5c4ae79e98761d0c967d32df1b802b93fb69b902d7651862ed0c30b54b0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1784552405,
                "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140960594,
                "url": "https://finnhub.io/api/news?id=b6dc2875bc5307f0ba48199fbd747c6354cd7ce2ee06b8136a7e109730aa2ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?",
                "category": "company",
                "datetime": 1784551980,
                "headline": "Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?"
              },
              {
                "id": 140959485,
                "url": "https://finnhub.io/api/news?id=caa721f340bbedb22a8e1f629ec48c39bebbd8df41106b2c1e3886e03dc1aeeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.",
                "category": "company",
                "datetime": 1784550548,
                "headline": "ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside"
              },
              {
                "id": 140959486,
                "url": "https://finnhub.io/api/news?id=0ac7bdf9b054c901569f5a3e9494d7e069264d131cc96da0afbfca9ffc8853d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- The peptide boom has all the markings of a mainstream wellness craze: podcast evangelists, celebrity converts and a billion-dollar market promising shortcuts to weight loss, muscle gain and a longer life. One major hurdle: actually buying them.Most Read from BloombergUS Strikes Iran in Escalating Campaign After Troops KilledThousands of Trucks Haul Iraq’s Oil Through Syria in Sign of Hormuz LegacyUS Strikes Iran to ‘Punish’ It for Attack That Killed 2 TroopsTrump Silent So Far on",
                "category": "company",
                "datetime": 1784540720,
                "headline": "‘Wild West’ of Untested Peptides Has Americans Paying in Crypto to Get Their Fix"
              },
              {
                "id": 140957134,
                "url": "https://finnhub.io/api/news?id=834955efcf3e0dfc6dd4efe7dbacc37aa4b93759005bff1d4df145b75988dac0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.",
                "category": "company",
                "datetime": 1784524695,
                "headline": "ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders"
              },
              {
                "id": 140956721,
                "url": "https://finnhub.io/api/news?id=4ec9c4508436a11a03dd62031182d629592016312c096aa5359e5fdd8add4abc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investors rotated into biotech, cybersecurity and insurance stocks with stronger growth prospects and earnings strength.",
                "category": "company",
                "datetime": 1784519541,
                "headline": "Why Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week?"
              },
              {
                "id": 140955502,
                "url": "https://finnhub.io/api/news?id=cbd0d7c6741205fab274c431ed86e67fa2eee1cf1b7b8cfcc5cfdc8cecd90bad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Maybe you should, too.",
                "category": "company",
                "datetime": 1784499600,
                "headline": "Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years"
              },
              {
                "id": 140951671,
                "url": "https://finnhub.io/api/news?id=edcfdddd5026455494e57595a336d293ee28d8d9a3b6d45f94f6c9f02447669b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.",
                "category": "company",
                "datetime": 1784467858,
                "headline": "3 Biggest Pharma Giants: Buy, Sell or Hold?"
              },
              {
                "id": 140951186,
                "url": "https://finnhub.io/api/news?id=80fc5a8e8ab67c57a31e836e926f232d8209eea2df7399f0f39be6109a2c9017",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1177165160/image_1177165160.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "We share our methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. Read the full list of picks here.",
                "category": "company",
                "datetime": 1784448900,
                "headline": "Our Top 10 High Growth Dividend Stocks - July 2026"
              },
              {
                "id": 140949509,
                "url": "https://finnhub.io/api/news?id=5fb9d2f14f8e04e052f30306d2cdfae47b8641f0181a82e7503118398ea08c1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock has delivered a 406.3% return over the past five years, yet its latest valuation checks point to an unusual tension as the Discounted Cash Flow (DCF) intrinsic value suggests the shares trade at a discount while the broader scorecard still leans expensive. A roughly 5x gain over five years can signal that a lot of optimism is already reflected in Eli Lilly’s share price, putting more focus on what investors are paying for that growth story today. Expectations tied to obesity,...",
                "category": "company",
                "datetime": 1784434501,
                "headline": "Eli Lilly (LLY) Stock Looks Undervalued On Fair Value Yet Full On Earnings"
              },
              {
                "id": 140946921,
                "url": "https://finnhub.io/api/news?id=9d3b43a29e84b5e519e515c72dbb2d5e62c0b424a0778946e11db185883228a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Viking's latest program seeks to push the envelope in weight loss efficacy.",
                "category": "company",
                "datetime": 1784405100,
                "headline": "Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1"
              },
              {
                "id": 140944469,
                "url": "https://finnhub.io/api/news?id=b5473b5e218fa09a16b46b6e5c24f774f88167fed580755ba05200e7f3171e3c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170932409/image_2170932409.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Discover dividend stocks and REITs to hedge AI bubble risk, geopolitics, and inflation. Click for this survey of great income choices and my ultimate pick.",
                "category": "company",
                "datetime": 1784379799,
                "headline": "AI Bubble Risks Make Dividend Stocks Attractive Again"
              },
              {
                "id": 140940064,
                "url": "https://finnhub.io/api/news?id=ac87da50615f1f010650baf3bb0f355a4da8dee30fd79e6f816f432ace33de66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.",
                "category": "company",
                "datetime": 1784338500,
                "headline": "The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss"
              },
              {
                "id": 140944614,
                "url": "https://finnhub.io/api/news?id=307e412a7579741a0fddefc62643bfcb67d4a3ac5c44974b5af6ec260e2e65c5",
                "image": "https://image.cnbcfm.com/api/v1/image/108335808-1784189865798-gettyimages-168597290-000023514379_Unapproved.jpeg?v=1784189915&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Startups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.",
                "category": "company",
                "datetime": 1784336402,
                "headline": "Fat cat? Weight-loss drugs may be coming for your overweight pet"
              },
              {
                "id": 140939161,
                "url": "https://finnhub.io/api/news?id=f57b9ce7b4402974f3ad4605a0ce95da73880c2e007cc7fb1d99cb560f207f71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.",
                "category": "company",
                "datetime": 1784325063,
                "headline": "The Real Question Buried Inside Merck Stock's Premium Price"
              },
              {
                "id": 140936300,
                "url": "https://finnhub.io/api/news?id=0619912c72d5845b90083140cf044c6cf4e0a8d961730467772681e825037883",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the",
                "category": "company",
                "datetime": 1784317490,
                "headline": "Sector Update: Healthcare Stocks Mixed Late Afternoon"
              },
              {
                "id": 140936218,
                "url": "https://finnhub.io/api/news?id=2c24fa0fdb2823735fb70b1842cf98957e158c30f0dfa40694d37dd6ddb56d04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is finally getting one up on its biggest rival.",
                "category": "company",
                "datetime": 1784314200,
                "headline": "Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win"
              },
              {
                "id": 140936302,
                "url": "https://finnhub.io/api/news?id=18a28194766e952b2004dfdc0dd7145a6e7447aafa867de1160f9d504358337e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Omada, an Eli Lilly partner, has soared more than 118% in just a few months, moving up the right side of a new base.",
                "category": "company",
                "datetime": 1784312238,
                "headline": "IPO Stock Of The Week: This Eli Lilly Partner Soars 118% In Three Months"
              },
              {
                "id": 140934447,
                "url": "https://finnhub.io/api/news?id=0f8a98820b8480ee66afcccb43f385accf435545db7516d0820ed90496f03d0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5.",
                "category": "company",
                "datetime": 1784307873,
                "headline": "Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal"
              },
              {
                "id": 140932951,
                "url": "https://finnhub.io/api/news?id=3d625afa6233dfda8012435905aba1d5df3aa390512caadad743af8838c21959",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GL",
                "category": "company",
                "datetime": 1784303310,
                "headline": "Eli Lilly Long-Term GLP-1 Franchise Faces Limited Generic Threat, UBS Says"
              },
              {
                "id": 140934448,
                "url": "https://finnhub.io/api/news?id=2db4e9cf90c0d1705ef9ac4634baeaab1cd71dde4d6eee17c8f6b2cdcd9d15d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.",
                "category": "company",
                "datetime": 1784302260,
                "headline": "Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout"
              },
              {
                "id": 140935407,
                "url": "https://finnhub.io/api/news?id=8826e67c12ece340942f8ddfe6e54dba131d04e0b4f590dec8e4fa46363ed686",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.lalettre.fr/fr/english-corner/2026/07/17/biotech-abivax-re-engages-investment-bank-centerview-for-big-pharma-takeover-talks,110842674-gra",
                "category": "company",
                "datetime": 1784297052,
                "headline": "'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre"
              },
              {
                "id": 140934449,
                "url": "https://finnhub.io/api/news?id=49c1fc4d706d395e829dcca23b21cca2a2089f0bfeb708ce15ccc631200e73e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Big pharma is making a big bet that a DMT nasal spray could succeed where daily Prozac pills fall short.",
                "category": "company",
                "datetime": 1784295000,
                "headline": "Prozac Maker Eli Lilly Just Bought a Psychedelics Company for $2.8 Billion — Here’s What It Could Mean for Mental Health"
              },
              {
                "id": 140936812,
                "url": "https://finnhub.io/api/news?id=ddb7b351f9f8705836d0230a60678ffe2dccb35e3ebcb9d758b026328760e71f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/17/benzinga-deal-dispatch2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.",
                "category": "company",
                "datetime": 1784294312,
                "headline": "Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternatives"
              },
              {
                "id": 140931552,
                "url": "https://finnhub.io/api/news?id=c6c15f7b9be6e91a2b6a69a2ea6d788ce5a261368bcf8eac4d0da56c2623b497",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by...",
                "category": "company",
                "datetime": 1784291820,
                "headline": "AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies"
              },
              {
                "id": 140931553,
                "url": "https://finnhub.io/api/news?id=2d514e51ba1de0bc99c88660e1ec2c4763504324cef780523cec5771378fb9f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Atlas Healthcare Fund managed by VST Capital, today highlighted a series of early conviction investment decisions that have defined its track record since launch — none more striking than its position in Eli Lilly and Company, entered at approximately $350 per share in 2020, years before GLP-1 receptor agonists became the most consequential pharmaceutical story of the decade. Eli Lilly now trades above $1,200, a gain of more than 246% from the fund's e",
                "category": "company",
                "datetime": 1784291760,
                "headline": "Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200"
              },
              {
                "id": 140931094,
                "url": "https://finnhub.io/api/news?id=a099441d45540ba3c35e09bde3e7d5680b7c75d851fa7e59d58cb3e5bbe54317",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "High growth momentum investing combines stocks with accelerating earnings and sales with technical breakouts. Eli Lilly (LLY) scores 8/10 on growth metrics and 10/10 technically, showing strong EPS growth and a consolidation pattern near support.",
                "category": "company",
                "datetime": 1784291424,
                "headline": "Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setup"
              },
              {
                "id": 140933581,
                "url": "https://finnhub.io/api/news?id=9a385d9550b1ee9b0a32e379b7afc16e0b87019409a9f9e52a697594be84c3b4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206372673/image_2206372673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "In this MoneyShow MoneyMasters Podcast episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the forces shaping the stock market - and the best profit opportunities for H2 2026.",
                "category": "company",
                "datetime": 1784291400,
                "headline": "Where To Invest Now In AI, Biotech, Small Caps, And Gold"
              },
              {
                "id": 140932383,
                "url": "https://finnhub.io/api/news?id=1f311ff4de315d7edf02a5775b38f1618c6853ffd33ba65344af3a27e9c15422",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2171515418/image_2171515418.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk is up 40% since April as oral Wegovy drives 2026 revenue upside, even vs. Eli Lilly. Click here to read this latest analysis of NVO stock.",
                "category": "company",
                "datetime": 1784286723,
                "headline": "Novo Nordisk: The Oral Wegovy Promise"
              },
              {
                "id": 140931554,
                "url": "https://finnhub.io/api/news?id=8e833337434d26111ded5c86258890a404cbdb9cb9562b348bdc437f86473f7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Companies In The Article Are:ASTS,ATAI,LLY,USB,CFG",
                "category": "company",
                "datetime": 1784285940,
                "headline": "Company News for July 17, 2026"
              },
              {
                "id": 140930770,
                "url": "https://finnhub.io/api/news?id=a9cb5ef50d046f2090172e80e8d04609cceed9932ff390ad50fd6714924f060a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.",
                "category": "company",
                "datetime": 1784284758,
                "headline": "The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea"
              },
              {
                "id": 140930771,
                "url": "https://finnhub.io/api/news?id=836d5c7983976ad670e85b957aa146049f95f7a3a187820e94b0ce8fbfb763dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company has agreed to acquire AtaiBeckley (NasdaqGM:ATAI) in a cash and contingent value rights deal valued at up to $3.8b, putting fresh focus on the stock’s risk and return trade off. See our latest analysis for AtaiBeckley. AtaiBeckley’s share price has reacted sharply to the Eli Lilly bid, with a 33.4% 1 day share price return on the announcement and an 84.75% year to date share price return. The 1 year total shareholder return of 156.27% contrasts with a 5 year total...",
                "category": "company",
                "datetime": 1784282890,
                "headline": "AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued"
              },
              {
                "id": 140930130,
                "url": "https://finnhub.io/api/news?id=3377160f9512a158105d6888c16a4984947f76362516a40b68a7a18e5253ab1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science. The prize at the centre of the deal is BPL-003, a nasal spray formulation of the psychedelic...",
                "category": "company",
                "datetime": 1784278860,
                "headline": "Eli Lilly's $3.8bn psychedelics bet is built on British science"
              },
              {
                "id": 140931555,
                "url": "https://finnhub.io/api/news?id=eea071582866f9a15bbd3fce4a5c994c426234c93c4ced9b24930135be030ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.",
                "category": "company",
                "datetime": 1784276667,
                "headline": "Compounders maintain a firm grip on the GLP-1 market"
              },
              {
                "id": 140934450,
                "url": "https://finnhub.io/api/news?id=d8e831dbde1b616936674d3f1873664b9939364f6123a996b22e4c9c5d69a664",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The deal gives Eli Lilly access to a ⁠psychedelic-based nasal spray that studies show curbs treatment-resistant depression in a single dose.",
                "category": "company",
                "datetime": 1784260860,
                "headline": "Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray"
              },
              {
                "id": 140928629,
                "url": "https://finnhub.io/api/news?id=072e3bfd616c4a91b32886e9b5950f43723730420d1b24eae7087362c56d8768",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Apple, AtaiBeckley and UnitedHealth Group jumped to yearly highs as positive company catalysts, Wall Street upgrades, and strong earnings pushed shares higher.",
                "category": "company",
                "datetime": 1784257358,
                "headline": "Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today?"
              },
              {
                "id": 140928243,
                "url": "https://finnhub.io/api/news?id=2f31ba932cf8c2ef816103d96af4705fe4ad4419fb7e0cbbf96e09fde5582eb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley climbed to a new four-year high on Thursday, as investors bought into its shares following news that Eli Lilly agreed to acquire the company for up to $3.8 billion. In intra-day trading, the stock surged to a record high of $7.22 before trimming gains to end the session just up by 33.40 percent at […]",
                "category": "company",
                "datetime": 1784247565,
                "headline": "AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly"
              },
              {
                "id": 140927325,
                "url": "https://finnhub.io/api/news?id=301fe28c4328fa8aefc664e07a0dc4705d04a534df1d54ea88fc3cfc6ca48ccc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The psychedelic drugmaker is being acquired.",
                "category": "company",
                "datetime": 1784241122,
                "headline": "Why AtaiBeckley Stock Soared Today"
              },
              {
                "id": 140927361,
                "url": "https://finnhub.io/api/news?id=f0ad3d9abaaef5ea1ab7af0402f99bf8fd9114bfa921579e54c90ed1027ccc23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) has seen a lot of bullish calls from Wall Street in July. Guggenheim, Truist, Bank of America, Bernstein, and JPMorgan all raised their price targets in the first half of the month. Then UBSwent higher than nearly all of them. UBS's call is worth watching closely because ...",
                "category": "company",
                "datetime": 1784240220,
                "headline": "UBS strongly resets Lilly stock target"
              },
              {
                "id": 140926080,
                "url": "https://finnhub.io/api/news?id=cb5c1dbdcf55a9a6cafff94dede8cd51aa88b20f29756e937b5a3a53fbbd37f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.",
                "category": "company",
                "datetime": 1784236745,
                "headline": "Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion"
              },
              {
                "id": 140926081,
                "url": "https://finnhub.io/api/news?id=e64f76c09adafa515f4830316766b320a68890737e1611bda2f9562417d8f44b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.",
                "category": "company",
                "datetime": 1784236020,
                "headline": "Why Healthcare Stocks Look Like a Haven in This Market"
              },
              {
                "id": 140927352,
                "url": "https://finnhub.io/api/news?id=4167742add66fef57c25a1a3ec1f1df12211a8746213a22c8fcf36bdd9e9a214",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.",
                "category": "company",
                "datetime": 1784232612,
                "headline": "Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today"
              },
              {
                "id": 140924321,
                "url": "https://finnhub.io/api/news?id=119450ead9605d895871452ae06130087451765f430cd380ee5fd7b703906adf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Acquisition could strengthen its neuroscience growth strategy",
                "category": "company",
                "datetime": 1784229240,
                "headline": "Eli Lilly Buys AtaiBeckley in $3.8 Billion Deal"
              },
              {
                "id": 140924322,
                "url": "https://finnhub.io/api/news?id=f6832ec569d0a664d884d1a33a1d3f3c524bb48490c7102b57a8d102368970dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The deal gives Lilly a late-stage psychedelic treatment for hard-to-treat depression.",
                "category": "company",
                "datetime": 1784228901,
                "headline": "Eli Lilly Buys AtaiBeckley for Up to $3.8 Billion"
              },
              {
                "id": 140924323,
                "url": "https://finnhub.io/api/news?id=17b5608d3f51824e6f9d24c6fa92f62b09becd541a01e49b7ac840853f496844",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly will pay $6.75 a share in cash, plus up to $1 billion in milestones",
                "category": "company",
                "datetime": 1784228342,
                "headline": "AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout"
              },
              {
                "id": 140924324,
                "url": "https://finnhub.io/api/news?id=d4761d29e079ca2623b2595a2c5f2d57d077d95edfc51ae51e3148fa11e22d4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.",
                "category": "company",
                "datetime": 1784224421,
                "headline": "Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug"
              },
              {
                "id": 140922620,
                "url": "https://finnhub.io/api/news?id=506a6d3987e001711e5073c22c88fb4144ff5020dcf521a69fb211198508d96b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) could see further momentum from positive amylin and tirzepatide data supporting its",
                "category": "company",
                "datetime": 1784222977,
                "headline": "Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says"
              },
              {
                "id": 140934029,
                "url": "https://finnhub.io/api/news?id=6d471199f096114656b56d4275e818cfbb2bc50be65cc8dedd009692dea7490f",
                "image": "https://image.cnbcfm.com/api/v1/image/108336287-17842371321784237129-47205829193-1080pnbcnews.jpg?v=1784237131&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Angelica Peebles joins 'Fast Money' to talk Eli Lilly investing in psychedelics.",
                "category": "company",
                "datetime": 1784222964,
                "headline": "Eli Lilly makes deal to buy psychedelics maker"
              },
              {
                "id": 140927363,
                "url": "https://finnhub.io/api/news?id=534d1a6b42c0334dbf8cafc3cad3ddeee016e95277c1851ed1e29c9c58f68b74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.",
                "category": "company",
                "datetime": 1784221847,
                "headline": "Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock"
              },
              {
                "id": 140934030,
                "url": "https://finnhub.io/api/news?id=4903171e17fb6e4bd355548bf865a7e1b4384a2630a8b581fff88ec10d9ab417",
                "image": "https://image.cnbcfm.com/api/v1/image/108336270-17842356001784235597-47205439738-1080pnbcnews.jpg?v=1784235599&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "UBS Michael Yee joins 'Closing Bell Overtime' to talk what could be ahead for M&A in the biotech space.",
                "category": "company",
                "datetime": 1784221679,
                "headline": "UBS Michael Yee talks biotech M&A outlook"
              },
              {
                "id": 140924325,
                "url": "https://finnhub.io/api/news?id=5cac8aeaadc80d5c961ac173e6177a0270891a7bded5d214f7cce61c7d5a7c54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.",
                "category": "company",
                "datetime": 1784220900,
                "headline": "NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity"
              },
              {
                "id": 140924212,
                "url": "https://finnhub.io/api/news?id=f1a83df4a460a5536afadd68c6d8b67158a8073b9c8875f11b1e6d8dfa1c018b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268438699/image_2268438699.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Johnson & Johnson’s strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ from Sell to Hold.",
                "category": "company",
                "datetime": 1784217215,
                "headline": "I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)"
              },
              {
                "id": 140920957,
                "url": "https://finnhub.io/api/news?id=2351160fc5075468e912fbaf74b5cfd23993b1dab4ff9e8a095cb195c5375131",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly.",
                "category": "company",
                "datetime": 1784215684,
                "headline": "Novo secures European approval for oral Wegovy to extend lead over Lilly"
              },
              {
                "id": 140920958,
                "url": "https://finnhub.io/api/news?id=9372875bc22c8d5be7b62ecdcd9c746c22eaad70edafc58e140ef5d483a1c10e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly tripped into the psychedelics space Thursday with the up-to-$3.8 billion acquisition of AtaiBeckley.",
                "category": "company",
                "datetime": 1784215422,
                "headline": "Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover"
              },
              {
                "id": 140920959,
                "url": "https://finnhub.io/api/news?id=5ca65886125060506cbb858303589dfe9feb9b4c15f873a6449871aa096ae0c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.",
                "category": "company",
                "datetime": 1784213040,
                "headline": "Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?"
              },
              {
                "id": 140920960,
                "url": "https://finnhub.io/api/news?id=dcb13dfe6397af2cbeaa74c64c0e9be36e47df6f995767a9a47b4d981caa671c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley (ATAI) shares surged more than 30% on Thursday after Eli Lilly (LLY) said it agreed to a",
                "category": "company",
                "datetime": 1784212910,
                "headline": "Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion to Expand Neuroscience Pipeline"
              },
              {
                "id": 140920961,
                "url": "https://finnhub.io/api/news?id=7c51533644ebaccb800577df079ea936536f8854a591482b9c7d88d8913b2420",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This acquisition marks Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline.",
                "category": "company",
                "datetime": 1784212487,
                "headline": "Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover"
              },
              {
                "id": 140923194,
                "url": "https://finnhub.io/api/news?id=3bfcec2845747bfa84db81187b47f21349674f00539e018d4eb899f75da08e0b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2283213489/image_2283213489.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "AtaiBeckley is being acquired by Eli Lilly at $6.75/share plus a $2.50 CVR—see the deal terms, milestone risks, and pipeline outlook. Click to read more.",
                "category": "company",
                "datetime": 1784211699,
                "headline": "AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline"
              },
              {
                "id": 140922932,
                "url": "https://finnhub.io/api/news?id=f3a4d2c7b17cefc1fe8780374c5ea4235b62e340ae9b8ef94162127e830a8ee3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2246468119/image_2246468119.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly and Company’s $3.8bn AtaiBeckley deal targets psychedelic mental health drugs, using GLP-1 cash to expand. Click for a look at LLY and ATAI stocks.",
                "category": "company",
                "datetime": 1784210838,
                "headline": "Eli Lilly Acquires Psychedelics Specialist AtaiBeckley - What Investors Should Know"
              },
              {
                "id": 140920962,
                "url": "https://finnhub.io/api/news?id=2cec22579047e245108d6c96f0282da91db225b322b2727f1dee0c8a8a992058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.",
                "category": "company",
                "datetime": 1784210761,
                "headline": "Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140920963,
                "url": "https://finnhub.io/api/news?id=c541a1270983bbfadf649c1e470b8de10d589441056b228134941f27c4d04128",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley stock surges after a Bloomberg report said Eli Lilly is in talks for a potential acquisition of the company, as investors await details of the deal.",
                "category": "company",
                "datetime": 1784210100,
                "headline": "ATAI Stock Soars on Reports of Potential Acquisition by Eli Lilly"
              },
              {
                "id": 140923118,
                "url": "https://finnhub.io/api/news?id=849660181dbdce21c5283300d80d1ffbd4882504fe8ef32a9722935ced89a103",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Konskie--Poland---September-07--2025-Uni.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.",
                "category": "company",
                "datetime": 1784208257,
                "headline": "UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses"
              },
              {
                "id": 140919684,
                "url": "https://finnhub.io/api/news?id=3c1d0c5d538a743bfd742623f0acc2aef62a674f35f910705872ef3bb868b52a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly announced it is buying AtaiBeckley in a bet on neuroscience and psychiatric pharmaceuticals.",
                "category": "company",
                "datetime": 1784208204,
                "headline": "Eli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapy"
              },
              {
                "id": 140919686,
                "url": "https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "What Could Push LLY Stock Higher From Here?"
              },
              {
                "id": 140919685,
                "url": "https://finnhub.io/api/news?id=8aaaa1ac492f93cd7e2c8a593e3ee9b65133645f1fcce9caf8568dc8cb52f96d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "The Real Engine Behind Johnson & Johnson Stock's Next Climb"
              },
              {
                "id": 140919687,
                "url": "https://finnhub.io/api/news?id=5df8c72991843888b0d0f3e05373e17ba374ae472704587f3c93dd3f1211506c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression...",
                "category": "company",
                "datetime": 1784205660,
                "headline": "AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion"
              },
              {
                "id": 140923161,
                "url": "https://finnhub.io/api/news?id=7717e8276d3ecf294779e1a9f6751a3055a6f5d9930c10cb23545b1fb4b77d34",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Depression-research-with-Magic-Mushrooms.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.",
                "category": "company",
                "datetime": 1784205378,
                "headline": "Why Is GH Research Stock Trading Higher on Thursday?"
              },
              {
                "id": 140923185,
                "url": "https://finnhub.io/api/news?id=2e178b8f0183c94552d1467239c3cd5546253744889021898e0045612cc8d0c0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Agitated-Depression-Mentioned.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.",
                "category": "company",
                "datetime": 1784205353,
                "headline": "AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal"
              },
              {
                "id": 140919688,
                "url": "https://finnhub.io/api/news?id=728ccf30fd24b99d2fc7994bdcb1c1b7b9149886f20bd71f8122f987d018edec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Psychedelic drugmaker  AtaiBeckley  was surging 34% ahead of the open Thursday after pharma giant  Eli Lilly  agreed a deal to buy the company.  AtaiBeckley shares were up 34.2% to $7.19 in premarket trading after the deal was confirmed.  Lilly will acquire AtaiBeckley for $6.75 per share in cash, plus up to $2.50 per share upon reaching certain developmental and regulatory milestones, the companies said in a press release.",
                "category": "company",
                "datetime": 1784205300,
                "headline": "AtaiBeckley Stock Is Soaring 34% as Eli Lilly Agrees to Buy Psychedelic Drugmaker"
              },
              {
                "id": 140922621,
                "url": "https://finnhub.io/api/news?id=acd6c4070d3b959de48eb3b93938602a11a6d376c65fde7307eafdb6227f04e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.",
                "category": "company",
                "datetime": 1784204340,
                "headline": "Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics"
              },
              {
                "id": 140920920,
                "url": "https://finnhub.io/api/news?id=19bf65b45f39954e551257debea7ac82f53fa593583892062a74d662bf2a32d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Oil prices traded just below $80 a barrel, despite further escalation in the Middle East",
                "category": "company",
                "datetime": 1784203260,
                "headline": "Nasdaq dragged by chip sell-off, Abbott, UnitedHealth lead risers"
              },
              {
                "id": 140919689,
                "url": "https://finnhub.io/api/news?id=0f4a56954429321eb46d94fab50f3184e620d6470ba0f7d0ac67f06b2cdc260c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Eli Lilly and Novo Nordisk.",
                "category": "company",
                "datetime": 1784203229,
                "headline": "The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?"
              },
              {
                "id": 140919690,
                "url": "https://finnhub.io/api/news?id=872dcdb1b794074e3c3b47d33c5b3c438dabc0540094151f4bc85d87bd2f0ffe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus",
                "category": "company",
                "datetime": 1784203200,
                "headline": "Kalshi Will Offer Sports-Style Betting on Drug Trial Results"
              },
              {
                "id": 140918818,
                "url": "https://finnhub.io/api/news?id=94cb59081a3cdc58b091e730c10afc5484d4a52ea3effceaf65f9adcc274f133",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting sentiment across the space.",
                "category": "company",
                "datetime": 1784202291,
                "headline": "Why Psychedelic stocks are surging today"
              },
              {
                "id": 140919691,
                "url": "https://finnhub.io/api/news?id=59934cad70f3745b16c56da035f9c0e9002d0712d52cd31505215670afb1098e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.",
                "category": "company",
                "datetime": 1784202165,
                "headline": "ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?"
              },
              {
                "id": 140919692,
                "url": "https://finnhub.io/api/news?id=625206521bb4122c1ac2b7cded2161b9bf732e2f6a52e5b991e1c4a1386ea320",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker’s recent buying spree.",
                "category": "company",
                "datetime": 1784202060,
                "headline": "Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion"
              },
              {
                "id": 140923186,
                "url": "https://finnhub.io/api/news?id=9fadc90c7b0f8fe8655d1d5482c0333b483cc9faa8b92ce60d0562c29fee2e65",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/16-7-2026-105158-thebambooworks-com.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings, driven by lucrative collaborations with multinationals\n\n\n\n\n\n\n\nimage credit: Bamboo Works\n\n\n\nKey",
                "category": "company",
                "datetime": 1784200998,
                "headline": "World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships"
              },
              {
                "id": 140918819,
                "url": "https://finnhub.io/api/news?id=5828136d0cf4723b248a203413fc988988a3f0c4636af496a69298f9b735370b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The deal gives Lilly access to a DMT-based nasal spray for treatment-resistant depression that has received FDA Breakthrough Therapy Designation",
                "category": "company",
                "datetime": 1784200206,
                "headline": "Eli Lilly to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion"
              },
              {
                "id": 140918820,
                "url": "https://finnhub.io/api/news?id=9ab32d97c646ba6ba69f92cf9f537853dcb1792d95d7e02b06dad4afda3ffc33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The radiopharma specialist will use earnings from this mega-round to progress ADVC001 and build manufacturing infrastructure to prepare for potential commercialisation.",
                "category": "company",
                "datetime": 1784199406,
                "headline": "Big pharma-backed AdvanCell pockets $315m to progress RLT to Phase III"
              },
              {
                "id": 140918821,
                "url": "https://finnhub.io/api/news?id=5b6ef3fb818440d1f94b2bdd6cc8cc2f68886b4120f8b122e133b9047f4d3c16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.",
                "category": "company",
                "datetime": 1784198700,
                "headline": "Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions"
              },
              {
                "id": 140918822,
                "url": "https://finnhub.io/api/news?id=11d0a6004abbc4f60986875de99d32415a01e49ccc22148cf31e5129be302058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "GH Research (NASDAQ:GHRS) shares climbed around 12% in premarket trading on Thursday after reports that Eli Lilly (NYSE:LLY) is in discussions to acquire psychedelic drug developer Atai Life Sciences (NASDAQ:ATAI), a development that sparked renewed investor interest across the sector. Potential acquisition lifts sentiment across psychedelic drug developersThe reported takeover talks sent Atai shares soaring by as much as 53% before the opening bell, with investors speculating that increased pha",
                "category": "company",
                "datetime": 1784198031,
                "headline": "GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)"
              },
              {
                "id": 140918823,
                "url": "https://finnhub.io/api/news?id=1d80b9a8d2ddd5cb96f08d8666a8551f85b05b8f0a688e6dbe05ec14246372fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley (NASDAQ:ATAI) shares jumped as much as 53% in premarket trading on Thursday after reports emerged that Eli Lilly (NYSE:LLY) is in discussions to acquire the psychedelic drug developer. Potential deal would broaden Lilly’s neuroscience portfolioAccording to BMO Capital Markets analyst Evan David Seigerman, an acquisition of AtaiBeckley would strengthen Eli Lilly’s presence in psychiatry while supporting its strategy of expanding beyond its established cardiometabolic business.",
                "category": "company",
                "datetime": 1784197852,
                "headline": "AtaiBeckley shares soar on reports of potential Eli Lilly takeover talks (ATAI)"
              },
              {
                "id": 140918824,
                "url": "https://finnhub.io/api/news?id=52867159ae7fa109db891021a556aec1c3c48625b31192263dc38364bafc2194",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Psychedelic drugmaker  AtaiBeckley  was surging 50% ahead of the open Thursday following a report that pharma giant  Eli Lilly  is nearing a deal to buy the company .  A deal, being negotiated at a premium, could be announced as early as this week, Bloomberg reported, citing people familiar with the matter.  The shares jumped 22% in a single day in April when President Donald Trump signed a directive to accelerate the Food and Drug Administration’s review of psychedelic drugs for serious mental illnesses.",
                "category": "company",
                "datetime": 1784194560,
                "headline": "This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks"
              },
              {
                "id": 140920374,
                "url": "https://finnhub.io/api/news?id=2d2f2d5b4ce3da3d4f480a303cd89cd505bb3ee9abc505cec2f253e909b24ab3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Wall-Street-New-York-Stock-Exchange.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "U.S. stock futures declined on Thursday, as the Dow Jones, Nasdaq 100, and S&P 500 indices fell, following Wednesday's higher close.",
                "category": "company",
                "datetime": 1784194134,
                "headline": "Stock Market Today: Dow Futures Rise, S&P 500 Falls As Trump Says Iran Wants To Negotiate— AtaiBeckley, J B Hunt, AST SpaceMobile in Focus (UPDATED)"
              },
              {
                "id": 140923188,
                "url": "https://finnhub.io/api/news?id=d85d188ac31f0be7b67de702da053ebe6f33ee097b1395995d39e56ab6610ae9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/GLP-1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Medicare enrollees $50. Across a year, that is the difference between roughly $600 and more than $4,000, and whether you",
                "category": "company",
                "datetime": 1784193389,
                "headline": "Medicare's $50 Weight-Loss Drug Window Opens In July: What Smart Enrollees Do Before 2027"
              },
              {
                "id": 140920423,
                "url": "https://finnhub.io/api/news?id=763f11df05c29ccbe7aa8e52eef03dc88147aed9e0448dcd28f80bcc2f6fc924",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Experts-Warn-On-Costly-Attacks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts recommended Vistra, Meta Platforms, and T. Rowe Price.",
                "category": "company",
                "datetime": 1784191992,
                "headline": "Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’"
              },
              {
                "id": 140918113,
                "url": "https://finnhub.io/api/news?id=7c0a4067213f0ac9dd79c30092bae763a6ffc4ab1541ce2be543007335604983",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Faced with the dual pressures of shifting consumer habits and emerging health trends, General Mills finds itself in a challenging market position.",
                "category": "company",
                "datetime": 1784188800,
                "headline": "Bear of the Day: General Mills (GIS)"
              },
              {
                "id": 140922147,
                "url": "https://finnhub.io/api/news?id=b91056a9332422e00ac8017cd0fa3160333dd105d6e7743970ef0634fcd4b5c3",
                "image": "https://image.cnbcfm.com/api/v1/image/107387028-1710350423351-gettyimages-1543156724-AFP_33PH3NQ.jpeg?v=1769095576&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "These are the stocks posting the largest moves in the premarket.",
                "category": "company",
                "datetime": 1784187631,
                "headline": "Stocks making the biggest moves premarket: UnitedHealth, TSMC, GE Aerospace, J.B. Hunt & more"
              },
              {
                "id": 140922148,
                "url": "https://finnhub.io/api/news?id=4c83505cb55e39a788e69d9c3fb67029d5d170d1e07d86a9410cc2a237477d2a",
                "image": "https://image.cnbcfm.com/api/v1/image/108335869-17842002661784200239-47196619443-1080pnbcnews.jpg?v=1784200265&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Angelica Peebles reports on the latest news on Eli Lilly.",
                "category": "company",
                "datetime": 1784187404,
                "headline": "Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion"
              },
              {
                "id": 140920376,
                "url": "https://finnhub.io/api/news?id=2a1ed56ceb68df1555e5665a012a2d69ddef0ef3e940852bb1e13d3c617a22e2",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) and AtaiBeckley Inc. (NASDAQ:ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for",
                "category": "company",
                "datetime": 1784184547,
                "headline": "Lilly To Acquire AtaiBeckley For $6.75 Per Share In Cash Plus Up To $2.50 Per Share In A Contingent Value Right Dependent Upon Milestones Related To The BPL-003 And VLS-01 Programs; Deal Valued At Up To ~$3.8B"
              },
              {
                "id": 140922149,
                "url": "https://finnhub.io/api/news?id=2480804da292e0ead07986655647a4d2a0d1deccf247abc5c72a5653a705b414",
                "image": "https://image.cnbcfm.com/api/v1/image/108230176-1764603822722-108230176-17637559702025-11-21t201158z_1546648356_rc261iafo6zz_rtrmadp_0_lilly-stocks.jpg?v=1779898152&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.",
                "category": "company",
                "datetime": 1784184353,
                "headline": "Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction"
              },
              {
                "id": 140920377,
                "url": "https://finnhub.io/api/news?id=a942ecb90b901feab023b2ff6db25f65861613b0b17a9d50cfd879cd158c2ef7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Front-Royal--Usa---May-27--2021-Highway-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7.9% in pre-market trading. Other top gainers include ATPC, TGHL, ATAI, DXST, KAPA, EHGO, HELP, VSA, and CMPS.",
                "category": "company",
                "datetime": 1784175957,
                "headline": "Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 249,
            "discarded_article_count": 222
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.9,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(14.7%→8%)；跌縮量(近10日3日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 2779733.3333333335,
              "down_days": 3,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 2187290,
              "avg_vol_20": 2357335,
              "avg_vol_30": 2779733.3333333335,
              "range_pct_10": 0.08049020856518985,
              "range_pct_20": 0.09957411678613425,
              "range_pct_30": 0.14733168380911918,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7868704432079815,
              "dist_to_20d_high": 0.07525704410969002,
              "down_shrink_days": 3,
              "breakout_level_20d": 1249.44995,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5463197493179526
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.5,
            "details": {
              "atrPct": 3.035259800409901,
              "turnoverUsdM": 5420.35733012976,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.LLY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 1085.28,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.1,
            "take_profit_price": 1213.191,
            "target_multiplier": 1.6,
            "technical_strength": 1.42,
            "take_profit_percent": 5
          },
          "positionPoints": 1.5,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.070519600819802,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 35.07,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.04
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -65.24
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0183
    },
    "kdj": {
      "d": 63.04,
      "j": 43.73,
      "k": 56.6,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 41.34
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 11395856,
      "recentSlope": -110874.4,
      "previousSlope": 143950
    },
    "rsi": 43.59,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 1138.265,
      "position": "SAR喺價下",
      "distancePct": 1.48,
      "previousTrend": "上升"
    },
    "ma50": 1144.7834,
    "macd": {
      "macd": 12.061050795966821,
      "trend": "中性偏多",
      "signal": 15.166543172728908,
      "histogram": -3.1054923767620863
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 1186.9292,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.91,
      "score": 6,
      "avgVolume": 2455877,
      "currentVolume": 4691244
    },
    "derived": {
      "ma20": 1188.053,
      "ma50": 1144.7834,
      "prevClose": 1210.02,
      "avgVolume10": 2377304,
      "avgVolume20": 2455877,
      "changePercent": -4.51,
      "avgVolumeForScore": 2455877
    },
    "ma_cross": {
      "ma20": 1188.053,
      "ma50": 1144.7834,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 1189.869,
      "prevMa50": 1141.4368,
      "spreadPct": 3.78,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 1137.7552,
      "upper": 1238.3508,
      "position": "中間"
    },
    "rsi_short": 46.91,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.91
    }
  }
}

{
  "close": 1155.42,
  "volume": 4691244,
  "changePercent": -4.51
}